


Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Graphical abstract



Authors

Han-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, ..., Hua-Jun Chen, Yi-Long Wu, Jin-Ji Yang

Correspondence

chenhuajun@gdph.org.cn (H.-J.C.), syylwu@live.cn (Y.-L.W.), yangjinji@gdph.org.cn (J.-J.Y.)

In brief

Wang et al. generated lung cancer organoids (LCOs) derived from human malignant serous effusions and tissues. The LCOs accurately represented original tumor features. Drug sensitivity tests were performed to predict clinical response. The results illustrated enormous value of LCO as an *in vitro* platform for personalized medicine of lung cancer.

Highlights

- Success rate of lung cancer organoids (LCOs) from malignant effusions exceeds 80%
- LCOs faithfully reflect the sample's pathologic and genomic features
- LCO-based drug sensitivity tests accurately predict clinical response to treatment
- LCO-based drug sensitivity tests represent temporal and spatial heterogeneity



Article

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Han-Min Wang,^{1,5} Chan-Yuan Zhang,^{1,2,5} Kai-Cheng Peng,^{1,3,5} Ze-Xin Chen,^{4,5} Jun-Wei Su,¹ Yu-Fa Li,¹ Wen-Feng Li,¹ Qing-Yun Gao,¹ Shi-Ling Zhang,^{1,2} Yu-Qing Chen,^{1,3} Qing Zhou,¹ Cong Xu,⁴ Chong-Rui Xu,¹ Zhen Wang,¹ Jian Su,¹ Hong-Hong Yan,¹ Xu-Chao Zhang,¹ Hua-Jun Chen,^{1,*} Yi-Long Wu,^{1,*} and Jin-Ji Yang^{1,2,3,6,*}

¹Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

²The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China

³School of Medicine, South China University of Technology, Guangzhou 510006, China

⁴Guangdong Research Center of Organoid Engineering and Technology, Guangzhou 510530, China

⁵These authors contributed equally

⁶Lead contact

*Correspondence: chenhuajun@gdph.org.cn (H.-J.C.), syylwu@live.cn (Y.-L.W.), yangjinji@gdph.org.cn (J.-J.Y.)

<https://doi.org/10.1016/j.xcrm.2022.100911>

SUMMARY

Predicting the clinical response to chemotherapeutic or targeted treatment in patients with locally advanced or metastatic lung cancer requires an accurate and affordable tool. Tumor organoids are a potential approach in precision medicine for predicting the clinical response to treatment. However, their clinical application in lung cancer has rarely been reported because of the difficulty in generating pure tumor organoids. In this study, we have generated 214 cancer organoids from 107 patients, of which 212 are lung cancer organoids (LCOs), primarily derived from malignant serous effusions. LCO-based drug sensitivity tests (LCO-DSTs) for chemotherapy and targeted therapy have been performed in a real-world study to predict the clinical response to the respective treatment. LCO-DSTs accurately predict the clinical response to treatment in this cohort of patients with advanced lung cancer. In conclusion, LCO-DST is a promising precision medicine tool in treating advanced lung cancer.







INTRODUCTION

Lung cancer is the second-most diagnosed cancer and the leading cause of cancer mortality, with over 600,000 deaths annually in China.^{1,2} Patients with advanced lung cancer who develop a malignant serous effusion (MSE) have a significantly worse prognosis, with an overall survival (OS) of 5.49 months, compared with 12.65 months for those without MSE.³ Over past decades, precision medicine, an approach that involves the formulation of regimens for treatment based on personalized factors and specific genetic targets, has been developed to improve therapeutic efficacy.^{4,5} Molecular-targeted therapy prolongs the OS of patients with advanced lung cancer and improves quality of life.^{6–8} Currently, the determination of personalized treatment regimens is strongly dependent on the results of molecular analytical approaches, particularly next-generation sequencing (NGS). NGS can detect tumor driver mutations that then allow the clinician to choose specific molecularly targeted drugs for cancer treatment.⁹ Molecular sequencing has historically relied on surgical and needle biopsy specimens. Studies have shown that the sensitivity and specificity of detecting epidermal growth factor receptor (*EGFR*) mutations in malig-

nant pleural effusion (MPE) samples are equivalent to the measurements performed on tumor tissue samples (>80%).¹⁰ Further, MPE is a reliable sample for detecting kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutations and anaplastic lymphoma kinase (*ALK*) rearrangements.^{11,12} It is also possible to detect any newly acquired genetic alterations using MSE.^{11,12}

Lung cancer is a complex disease that exhibits phenotypic and genotypic diversity in different patients,^{13,14} presenting considerable challenges to the use of precision medicine. Non-small cell lung cancer (NSCLC) is the most extensively studied lung cancer subtype, although only 30% of patients harbor actionable mutations,¹⁵ and not all these patients can benefit from targeted therapy. Alternatively, some targeted anti-cancer agents have off-target effects as well.¹⁶ Patients without actionable mutations may benefit from targeted therapeutic drugs such as EGFR tyrosine kinase inhibitors (TKIs)¹⁷ or poly (ADP-ribose) polymerase (PARP) inhibitors.¹⁸ Therefore, it is imperative to establish a preclinical model that simulates the morphologic and genomic features of the original tissue to predict the clinical outcomes of targeted therapy.





(legend on next page)

There has been a considerable focus on establishing reliable preclinical models to evaluate a tumor's response to chemotherapeutic or targeted agents. These models include cell lines,¹⁹ genetically engineered mouse models,²⁰ organotypic tissue slice cultures,²¹ and patient-derived xenografts (PDXs).^{22,23} Although traditional tumor cell lines can be used to establish preclinical models, they are insufficient to represent complex tumors because of the lack of cell-to-cell interactions.²⁴ Conversely, PDX can retain the structure and genetic characteristics of the original tumor and simulate a similar tumor microenvironment.²⁵ However, PDXs, as well as genetically engineered models,²⁶ are costly and time-consuming and require the sacrifice of a large number of experimental animals. Therefore, a preclinical model in which both maintenance and expansion are easily established is essential for translational medicine. Patient-derived organoids (PDOs) use three-dimensional (3D) structures that can accurately simulate the heterogeneity and diversity of tumors, show a high degree of genotypic and phenotypic consistency with the original clinical specimens, exhibit a response to antitumor drugs that mimics the patient's expected response, and are available within a short period of time.^{27–29}

In previous studies, organoids have been successfully cultured in a series of primary tumors, including colonic,^{30,31} uterine,³² ovarian,³³ pancreatic,^{34,35} breast,³⁶ and other solid tumors. Recently, organoids derived from primary lung tumors have been described.^{37–39} In the past, surgical specimens were used to establish lung cancer organoids (LCOs), but these were not easily available for advanced lung cancer. In addition to the establishment and validation of LCOs, studies focused on developing automated approaches, such as microarrays and microfluidic chips, to perform organoid-based drug tests in a short period of time.^{40,41} A recent study showed that the response outcomes of targeted therapy using lung adenocarcinoma (ADC) organoids were highly correlated with the real clinical response,⁴² revealing the potential of LCOs as a tool in personalized medicine.

Success rates of LCO culture ranged from 7% to 87%, and MSE could be an ideal source.⁴³ However, the accuracy of LCO-based drug sensitivity tests (LCO-DST) to predict clinical response remains unclear. In this study, we successfully generated 160 LCOs derived from tumor tissue specimens and MSE samples. We aimed to generate viable LCO models using tumor tissue or MSE samples, validate the reliability of the models with respect to their pathological and molecular features, and formulate personalized treatment strategies for advanced lung cancer using the results of the drug sensitivity tests (DSTs).

RESULTS

Summary of the generation and pathological analysis of patient-derived lung cancer organoids

In our study, 214 samples for the generation of organoids were collected from 107 patients with advanced cancer between October 1, 2019, and September 30, 2021. LCOs were cultured using an existing method with slight modifications.⁴⁴ We successfully established 162 PDOs (Figure 1A, Table S1) with a success rate of 75.7% (Figure S1). Following the exclusion of samples from two patients with breast cancer, 160 samples were finally included in the in-depth analysis. LCOs of different types were generated, including 127 ADCs, 10 squamous cell carcinomas (SCCs), 10 small cell lung carcinomas (SCLCs), 12 adenocarcinomas (ASCs), and one pulmonary sarcomatous carcinoma. The LCOs in this cohort were mainly derived from MSE (132 of 162), including pleural fluid samples (103 of 132), ascitic fluid samples (15 of 132), and pericardial effusion samples (14 of 132). Further, 18 specimens were isolated from surgically resected biopsies of primary or metastatic lesions, which were mainly from lymph nodes. Ten specimens were obtained by core needle biopsy.

We attempted to analyze the potential causes of culture failure in 52 LCOs. Insufficient cells was one of the most common factors. Furthermore, univariate and multivariate analysis showed pathology and sampling type were independent influencing factors (Table S2). Lung adenocarcinoma and MSE are favorable for successful culture (Table S3).

Hematoxylin-eosin (H&E) staining and immunohistochemistry (IHC) were performed to validate the organoids and compare their morphology and pathology with the original tissue. IHC markers were selected from those that are routinely used for diagnosis of lung cancer subtypes. H&E staining (Figure 1B) and IHC (Figures 1C–1E) suggested that the LCOs retained the histopathologic characteristics of the original tumor tissue or MSE. For instance, ADC-derived LCOs were observed in clusters, with subtle cytologic features such as prominent nucleoli and cuboidal nuclear morphology, forming acinar structures and retaining the characteristics of primary ADC tissue (Figure 1B). Further, ADC-derived LCOs expressed classic ADC markers, including cytokeratin 7 (CK7), thyroid transcription factor 1 (TTF-1), and napsin A (Figure 1C).⁴⁵ LCOs derived from SCC were obtained from surgically resected lung lesions (P-106) and showed strong expression of IHC indicators P40, P63, and CK5/6 (Figure 1D). The LCOs derived from SCLC showed small cell morphology and less periplasm, and expressed neuroendocrine markers such as CD56, synaptophysin (Syn), CgA, and TTF-1 (Figure 1E). These data indicate that LCOs can maintain the

Figure 1. Study flow chart and preservation of lung histopathology in LCOs

(A) Study workflow. See also Figure S1 and Tables S1–S3.

(B) Bright-field images of LCOs (left column), H&E staining of advanced lung cancer-derived LCOs (middle column), and the primary tumor malignant effusions (right column), including the pericardial effusion, pleural effusion (PE), and ascitic effusion (AE). Scale bars, 100 μ m.

(C) IHC staining of the adenocarcinoma-derived LCOs as well as the original tissue with classic subtype markers TTF-1 (left column), CK7 (middle column), and Napsin A (right column). Scale bar, 50 μ m.

(D) IHC staining of CK5/6, P40, and P63 in squamous cell carcinoma. Scale bar for the tissue, 50 μ m. Scale bar for the LCO, 20 μ m.

(E) IHC staining of TTF-1, Syn, CgA, and CD56 markers of small cell lung cancer. Scale bar, 50 μ m.




Figure 2. Genomic profiling of LCO samples

(A) The overlap of somatic alteration in effusion and LCO samples. Blue indicates alterations detected from both sources, pink indicates alterations that were present only in the effusion samples, and scarlet indicates alterations that were present only in the LCO samples. See also Figures S2A and S2B, and Tables S1 and S2. (B) The difference of maxAF between effusion and LCO samples.

(C) The concordance for somatic alterations between effusion and LCO samples.

(D) The difference of TMB between effusion and LCO samples. p values are determined using the two-tailed t-test or Mann–Whitney U test for continuous variables.

(E) Correlation between effusion-based and LCO-based TMB (Pearson correlation coefficient, two-tailed). ADC, adenocarcinoma; ASC, adenosquamous carcinoma; CN, copy number; F, female; Indel, small insertion and deletion; LCO, lung cancer organoid; LGR, large genomic rearrangements; M, male; maxAF, maximum allele frequency; MSE, malignant serous effusion; SCC, squamous cell carcinoma; TMB, tumor mutational burden.


morphological and pathological features of the original tumor and mirror its individual characteristics.

The concordance for genomic profiling between MSE and MSE-derived LCOs


NGS was performed for 25 patients to test the concordance of genetic profiles between LCOs and the original samples. The clinical characteristics of the cohort are summarized in Table S4. Somatic mutational profiling of the effusion and LCO samples was performed. Alterations in the effusion and matched LCO samples are shown in Figure 2A. Collectively, 157 somatic alterations spanning 77 genes were identified in the effusion

samples, including 100 single nucleotide variants (SNVs), 11 indels, 28 copy number variations (CNVs), four large genomic rearrangements (LGRs), and 14 fusions. Tumor protein 53 (*TP53*), *EGFR*, and retinoblastoma1 (*RB1*) were the most frequently mutated genes, occurring in 69% ($n = 18$), 69% ($n = 18$), and 19% ($n = 5$) of effusion samples (Figure S2A, Table S5). Moreover, 143 somatic mutations spanning 73 genes were identified in the LCO samples, including 93 SNVs, 11 indels, 26 CNVs, four LGRs, and nine fusions. *EGFR*, *TP53*, and *RB1* were the most frequently mutated genes, occurring in 65% ($n = 17$), 58% ($n = 15$), and 15% ($n = 4$) of the LCO samples, respectively (Figure S2B). Among those alterations, 64 mutations (30.9%) were


A




B




C




D




E




F




G




H




I



J



K



(legend on next page)

effusion-specific, 50 alterations (24.2%) were LCO-specific, and 93 mutations (44.9%) were shared between the two media. The alteration detection rates were comparable between the effusion and LCO samples (96.2% versus 80.7%, $p = 0.19$). No significant difference in the median maximum allele frequency (AF) between the effusion and LCO samples was observed (31.1% versus 34.0%, $p = 0.98$, Figure 2B). Next, the concordance of somatic alterations between MSE and LCOs was analyzed. Among the 20 effusion and matched LCO samples harbouring somatic alterations, 93 somatic alterations were detected in both effusion and LCO samples, 39 alterations were effusion-specific, and 41 alterations were LCO-specific. These data resulted in a by-variant sensitivity of 70.5% (93 of 132) with a positive predictive value of 69.4% (93 of 134) in LCO samples when the genomic profile of matched effusion samples was used as a reference (Figure 2C). Eleven matched LCOs and effusion samples had tumor mutation burden (TMB). A comparable TMB was observed between the two media (1.99 mutations/Mb for both, $p = 0.89$, Figure 2D). Further, LCO-based TMB was positively correlated with effusion-based TMB (Pearson's $r = 0.68$, $p = 0.02$, Figure 2E). Cumulatively, these findings revealed acceptable concordance of genomic profiling between the effusion and LCO samples.

LCOs predict a personalized response to targeted therapy

In most patients, therapeutic regimens were personalized based on factors such as genetic features and previous treatments. Moreover, *in vitro* drug screening strategies were also tailored to individual patients. Fifty-four LCOs derived from 36 patients whose clinical regimens were identical to LCO-DST results were divided into four categories: osimertinib, chemotherapy, dual-targeted therapy, and other targeted therapy groups. The capability of LCO-DST to discriminate between clinically sensitive or resistant patients was determined using receiver operating characteristic (ROC) analysis. The predictor was LCO sensitivity to osimertinib, chemotherapy, dual targeted therapy, and other targeted therapy treatment. The concordances of response were 86.7% (13 of 15), 83.3% (10 of 12), 100% (10 of 10), and 70.6% (12 of 17), respectively (Table S6), with overall 84.0% (95% CI, 63.08%–94.75%) sensitivity, 82.8% (95% CI, 63.51%–93.47%) specificity, and 83.3% accuracy for LCO-DST (Figures 3A, 3B, S3A, and S3B). Drug response heatmap of six LCOs from four patients suggested personalized differ-

ences in patient responses to anti-cancer agents and a relatively high consistency in responses between different LCOs derived from the same patient. Generally, the half maximal inhibitory concentration (IC_{50}) values of chemotherapy agents were higher than those of targeted therapeutic agents (Figure S3C).

In the osimertinib cohort, osimertinib was selected as the next-line treatment for 12 patients (Figure 3C), and the sensitivity of osimertinib was tested on 15 LCOs generated from these patients (Figure 3D). Generally, the IC_{50} of the progression disease (PD) and partial response (PR) groups could be distinguished significantly, with an area under the curve (AUC) value of 0.94 in ROC analysis (Figures 3E and 3F). The clinical response of most patients was accurately predicted using the LCO-DST. For example, P-41 was diagnosed with stage IVA ADC harboring *EGFR* 19del. First-line treatment was icotinib. After PD, the LCO-DST suggested the potential beneficial effect of osimertinib ($IC_{50} = 0.10 \mu\text{M}$). In the real world, osimertinib was used in the following treatment of this patient, and achieved sustained PR (Figure 3G). Further, the LCO-DST could also predict resistance to targeted therapy agents. For instance, P-59, with stage IVB ADC harboring *EGFR* L858R, progressed after treatment with erlotinib, icotinib, and gefitinib. *EGFR* T790M was found and osimertinib was chosen as the next-line treatment according to clinical guidelines. However, LCO-DST indicated resistance to osimertinib ($IC_{50} = 4.37 \mu\text{M}$) *in vitro*. Unfortunately, the disease progressed rapidly in only 4.5 months (Figure 3H). Furthermore, these results showed that the reduction in tumor volume was correlated with IC_{50} values (Figure S3D), suggesting that this approach may also predict the outcome after anti-cancer treatment.

Four patients with *ALK* fusion were enrolled in LCO-DST analysis, including one untreated patient and three treated patients. All LCO-DST results were consistent with the clinical response (100%, 5 of 5). For example, P-63 was diagnosed with stage IVA ADC harboring echinoderm microtubule-associated protein-like 4 (*EML4*)-*ALK* fusion. Second-generation *ALK*-TKIs, ceritinib and SAF-189s, were sequentially indicated and achieved PFS of 33.7 and 22.8 months. LCO-DST performed using MPE samples after the progress of second-line treatment predicted resistance to alectinib. SAF-189s was also ineffective *in vitro* (Figures 3I and 3J). Nevertheless, the LCO-DST were not considered when deciding the next-line treatment; alectinib was still decided as the third-line treatment. Intracranial metastases increased significantly, which led to disease progression. Another patient with

Figure 3. Comparison of LCO-based drug screening and clinical response

See also Figure S3 and Table S6.

- (A) Flowchart of LCO-DST and clinical follow-ups in this study.
- (B) The overall correlation between LCO-DST sensitivity and clinical response.
- (C) Swimming graph of the progression-free survival (PFS) of patients who received osimertinib treatment.
- (D) Dose-effect curves of LCO based on *in vitro* sensitivity of osimertinib.
- (E) Violin plot of the IC_{50} values of osimertinib for clinical PR and PD groups.
- (F) Receiver operating characteristic (ROC) analysis of osimertinib LCO drug tests showed an area under the curve (AUC) of 0.94 with a p value of 0.0047. p values are determined from the normal distribution (two-tail) for the comparison to a chance-level ROC curve (AUC = 0.5).
- (G) Computed tomography (CT) scan of P-41 at the baseline, PR, and confirmed PR stages.
- (H) CT scan of P-59 at the baseline, SD, and PD stages.
- (I) Dose-effect curve of lorlatinib and SAF-189s for LCOs derived from P-63.
- (J) CT scan of the brain and thoracic cavity of P-63 at baseline and PD stages.
- (K) Dose-effect curves of the EP regimen (etoposide and paclitaxel) for LCOs derived from P-3, P-50, P-65, P-83.

*: $p < 0.05$.

ALK fusion (P-27) was previously resistant to alectinib and showed insensitivity to alectinib in the LCO-DST (Figure S3E).

Cases with other mutations, such as *ROS1* (P-25), *HER2* (P-75), *MET* exon 14 skipping (P-86 and P-105), and *BRAF* (P-95), were also enrolled in LCO-DST analysis (Table S6) and provided accurate predictions of the clinical response.

These results illustrate that LCOs may predict the clinical response to targeted therapy, both in untreated and treated patients. Although a limited number of regimens for each drug test may not accurately indicate which treatments are recommended, it is still critical for these patients to avoid ineffective therapies because of unnecessary side effects, time consumption, and resource expenditure.

LCOs predict a personalized response to chemotherapy

A correlation between the LCO drug screening test results with the real clinical response to chemotherapy has been previously reported.⁴⁰ Here, we reported the data of nine patients in whom chemotherapy was recommended as the next-line course of action.

Of these, four patients had ADC and underwent treatment with TDM1 (P-85), nab-paclitaxel (P-81), a PC regimen (pemetrexed and carboplatin) (P-25), and an EP regimen (etoposide and cisplatin) (P-3). Three out of four patients with SCLC underwent EP treatment (P-50, P-65, and P-83), and P-73 was treated with nab-paclitaxel. Among patients who underwent EP treatment, P-3 was diagnosed as ADC while others were diagnosed as SCLC. They were treated with the same regimen and had different outcomes. P-3 and P-65 both achieved PR while PD was observed in P-50 and P-83. The actual clinical response was predicted by the LCO-DSTs, where EP treatment inhibited both the LCOs derived from P-3 and P-65 but failed to inhibit the LCO derived from P-50 and P-83 (Figure 3K). These results suggested that *in vitro* testing of LCOs with chemotherapeutic agents can reflect the clinical response to chemotherapy.

LCOs derived from multiple samples reveal stability and heterogeneity

Apart from the success rate and the degree of purity of the models, another challenge in the use of tumor organoids for drug screening is experimental stability. Inter- and intra-tumor heterogeneity has been widely considered. In this study, we collected different samples from the same patient to explore the stability and heterogeneity of the LCO drug response. First, MSE samples were extracted from the patient at different times, the LCOs were established, and DSTs were performed. The cell count generally decreased with sampling time, but the establishment of the LCO models was not affected (Figure S4A). The genomic profiles of LCO samples with different culture durations were analyzed (Figure S4B). The time intervals between different sampling times ranged from 1 to 9 days. P-51 had three LCO samples collected on days 1, 2, and 3. P-78 and P-100 each had two LCO samples collected on days 1 and 2. P-101 had two LCO samples collected on days 4 and 9. For P-51, the consistency of somatic alterations among the three LCOs was 81.25% (13 of 16), with *MYC* amplification and *WT1* amplification being identified only in the LCO collected on day 1, while *IL7R* amplification was not identified in the LCO collected on day 3.

Moreover, the same alterations were observed in the LCO samples obtained from the remaining three patients (P-78, P-100, P-101). Collectively, these findings indicated a high concordance for genomic profiling among LCO samples obtained at different sampling times, suggesting that the LCO may be an optimized stable *in vitro* model of NSCLC (Figure 4A).

Next, we investigated the concordance for genomic profiling of tissue samples, effusion samples, and LCOs obtained from five patients. In P-51, 13 SNVs were detected in the tumor tissue samples, and 12 SNVs were detected in both MSE and LCOs; however, only two out of 12 CNVs were detected in both MSE and LCOs (Figure 4B). High concordance for SNVs between tissue and effusion/LCO samples was also observed in P-87 and P-96 (Figures 4C and 4D). Low concordance for CNVs between tissue and effusion/LCO samples was observed in P-60 and P-100 (Figures 4E and 4F). These findings suggest that SNVs, rather than CNVs, may be accurately detected in effusion/LCO samples.

In terms of the *in vitro* LCO drug response, stability was maintained across the continuous samples. P-51, with advanced SCC, had a large volume of MPE that was collected over 3 consecutive days. Cell density from the MPE decreased over time, and the number of organoid formations was also affected, although the cell density in the LCO cultures remained the same (Figure 4G). The LCO-DST yielded stable results for different samples. Three LCOs were minimally inhibited by the combination of nab-paclitaxel, which had also been proven to be clinically ineffective, while a phosphoinositide 3-kinase (PI3K) inhibitor, GDC-0941, showed a stronger inhibitory effect (Figures 4H and 4I). The LCOs derived from MSE samples seemed to exhibit large differences from tissue-derived LCOs, such as the LCOs derived from the MPE of P-33, which were loose and irregular. The LCOs derived from the lymph nodes of the same patient showed tighter and more regular shapes (Figure 4J). Lymph node-derived LCOs were also more sensitive to DST (Figure 4K), and the patient who underwent treatment with alectinib achieved a PR on clinical evaluation, consistent with the drug sensitivity test result (Figure 4L). In the case of different MSE samples, the LCO-DST often showed the same trend with respect to the dose-effect relationship. For instance, two samples were collected from MPE and ascitic effusion, and the morphological features of LCOs were slightly different: the MPE-derived LCOs showed vacuolated and solid appearances, while the ascitic effusion-derived LCOs were solid (Figure 4M). The DST of ascitic effusion-derived LCOs were slightly more sensitive than those of the MPE-derived LCOs, although the difference between the sensitivities was not significant (Figure 4N).

LCO drug screening represents the clinical response of dual-targeted therapy

Resistance to a single anti-cancer agent is common in patients with advanced lung cancer. It would be helpful if LCO-DST could predict the effect of combinational therapy *in vitro*. Several cases in our study presented with progressive lung disease. LCOs were obtained, and combination therapy regimens were tested. P-60 was diagnosed as Stage IVB lung ADC (Figures 5A and S5A) with *EGFR* L858R mutation and *MET* copy number gain (5.0) detected in cerebrospinal fluid at baseline. This patient experienced worsened dizziness and vomiting with enlarged brain metastases after taking osimertinib; it seemed that osimertinib may not the




Figure 4. Stability and heterogeneity of LCOs

(A) Concordance for somatic alterations detected in MSE and LCO samples at different sampling times in four patients. See also Figure S4. ADC, adenocarcinoma; CN, copy number; D, day; F, female; Indel, small insertion and deletion; LCO, lung cancer organoid; LGR, large genomic rearrangements; M, male; MSE, malignant serous effusion; P, patient; SCC, squamous cell carcinoma.

(B) The concordance of SNVs between MSE and LCO of P-51.

(C) The concordance of SNVs between MSE and LCO of P-87.

(D) The concordance of SNVs between MSE and LCO of P-96.

(E) The concordance of SNVs between MSE and LCO of P-60.

(F) The concordance of SNVs between MSE and LCO of P-100.

(G) CT scan of P-51 presents the location of the pleural effusion (PE) and bright-field images of the PE-derived LCOs on days 1, 2, and 3.

(H) Dose-response curve of Nab-PTX plus carboplatin and GDC-0941 for LCOs of P-51.

(legend continued on next page)

optimal choice for him. One LCO (P-60-O1T) derived from lymph node and three (P-60-O2E, P-60-O3E, and P-60-O4E) derived from consecutive pericardial effusion (day 1, 4, 5) were successfully cultured and DST were performed (Figure 5B). IC₅₀ of osimertinib combined with savolitinib were 1.32, 0.71, 0.25, and 0.24 in these four LCOs, respectively. Compared with IC₅₀ of osimertinib (1.82, 1.15, 0.25, and 1.30, respectively) and savolitinib (only performed in P-60-O3E and P-60-O4E, which were 11.59 and 17.61), the result revealed that osimertinib plus savolitinib may be superior to osimertinib or savolitinib monotherapy for this patient. Interestingly, the patient was given with osimertinib plus savolitinib since *MET* amplification were further confirmed in MSE and LCO via fluorescence *in situ* hybridization (FISH), immunofluorescence staining, and IHC (Figures 5C, 5D, and S5B), and achieved confirmed PR (Figure 5E). P-61 was diagnosed as stage IVA lung ADC with *EGFR* 19del at baseline (Figure 5F). The patient underwent first-line treatment with icotinib and second-line treatment with osimertinib because of an acquired T790M mutation. After the development of drug resistance, the patient underwent dual-targeted therapy, including osimertinib and cabozantinib. Tumor evaluation revealed PR after 45 days of dual-drug therapy (Figure 5G). NGS confirmed the presence of rearranged during transfection (*RET*)-*CCDC6* fusion (Figure 5H) besides *EGFR* 19del and T790M. DST of LCOs derived from pleural effusion (P-61-O1E, P-61-O2E, P-61-O3E) and ascitic effusion (P-61-O4E, P-61-O5E) during the same period showed that IC₅₀ of osimertinib combined with cabozantinib were 0.15, 0.22, 0.16, 0.33, and 0.44, respectively, while IC₅₀ of osimertinib combined with BLU667 were 0.03, 0.02, 0.01, 0.03, and 0.24, which indicated that osimertinib combined with cabozantinib/BLU-667 significantly inhibited tumor growth (Figure 5I). These cases suggested that the LCO-DST has the potential to predict effective combination treatment regimens.

Proteomics landscape of LCOs reveals the molecular mechanisms of dual-targeted therapy

Although the effect of combination treatment with EGFR and RET inhibitors has been demonstrated in LCO drug screening assays, the underlying molecular mechanisms remain unclear. Therefore, 4D label-free high-throughput proteomic analysis was performed. We identified 39,312 unique peptides in the 287,153 spectra. A total of 4,865 proteins were identified and, of these, 4,833 were quantified. The quantified proteins were divided into four groups (4818, 4787, 4785, and 4833), in which organoids were treated with osimertinib, BLU-667 combination treatment with osimertinib, BLU-667 (combo group), and 0.1% dimethyl sulfoxide, respectively. The results of the principal-component analysis (PCA) indicated that the expression levels of the different treatment groups were different, suggesting diverse effects (Figure 6A). In terms of the differentially expressed proteins (DEPs), 119 proteins were significantly altered

in the combo regimen compared with the control group (fold change >1.2, $p < 0.05$), including 26 upregulated proteins and 93 downregulated proteins (Figure 6B). However, when treated with a single agent, osimertinib or BLU-667, the number of DEPs was 154 (Figure 6C) and 285 (Figure 6D). In terms of the cellular location of the DEPs, all three treatment groups showed the same trend of protein expression, of which the number of nuclear proteins was the highest in the DEPs, followed by that of cytoplasmic and cytomembrane proteins. These results suggest that the alteration of protein expression with all three treatments aimed to regulate nuclear functions, including gene expression.

In terms of the function of DEPs, alterations in several protein families are closely related to the survival of tumor cells. The combination of osimertinib and BLU-667 resulted in a dramatic increase in the expression of caspase 3, the critical factor triggering cell apoptosis, while the expression of other caspase family members, such as caspase 8 and caspase 10, also increased after treatment with the combination regimen (Figure 6E). *RET* rearrangement is a critical factor in EGFR-TKI resistance because of the common downstream cascade. RET TKIs were also combined with the third-generation EGFR-TKI osimertinib as a treatment regimen for patients with *EGFR-RET* duo mutation. However, the underlying molecular mechanisms remain unclear. Proteomic analysis by 4D liquid chromatography-tandem mass spectrometry (LC-MS/MS) showed that the expression of the downstream proteins of EGFR and RET were downregulated, such as RAC, PI3K, and MEK (Figure 6F), suggesting their role in tumor cell survival. Another key pathway altered in the treatment was the Hippo pathway, which is critical for tumor growth and survival. Both MOB1 and MST1/2 levels were significantly decreased by either separate or combined treatment with BLU-667 and osimertinib. The level of YAP, a key transcription factor for survival-related genes, decreased after treatment with the combination regimen of BLU-667 and osimertinib (Figure 6G). These results suggested that the combination treatment significantly triggered cell death compared with treatment with single reagents (Figures S6A–S6F).

DISCUSSION

There are limitations in formulating treatment strategies based on the results of genetic profile and other biomarkers.^{46,47} In many cases, particularly with primary drug-resistant patients, the molecular mechanisms of the response to therapy, or lack thereof, are unclear. Therefore, a precise approach to accurately predict the clinical response is imperative in the use of precision medicine for the treatment of lung cancer. Previous studies have indicated that MSE-derived organoids and other *in vitro* models are potential materials for predicting the clinical efficacy of treatment.^{48,49} Our results suggest that the LCO models provide a personalized platform for the application of both targeted

(I) CT scans of P-51 at the baseline and after Nab-PTX + carboplatin treatment.

(J) CT scan of P-33 shows the location of the PE and lymph node (LN) and bright-field images of the PE- and LN-derived LCOs.

(K) Dose-response curve of crizotinib, alectinib, and lorlatinib for P-33 LCOs.

(L) CT scan of P-33 at the baseline and after alectinib treatment.

(M) CT scan of P-30 shows the location of the ascitic effusion (AE) and PE, as well as the bright-field images of the AE- and PE-derived LCOs.

(N) Dose-response curve of osimertinib and osimertinib + cabozantinib for P-30 LCOs.




Figure 5. LCOs predict dual-targeted therapy for drug-resistant cases

See also Figure S5.

(A) Disease progression of P-60.

(B) Dose-effect curve of LCOs derived from the lymph node (LN) and pericardial effusion of P-60.

(C) FISH of *MET* amplification of the LN, pericardial effusion, and LCOs derived from pericardial effusion and the LN.

(D) Immunofluorescence staining of MET and DAPI, and immunohistochemistry staining of *EGFR* L858R for LCOs derived from pericardial effusion and lymph nodes of P-60. Scale bar, 20 μm .

(E) CT scans indicating the progression of the disease of P-60.

(F) Disease progression of P-61.

(G) CT scans of P-61.

(H) FISH of RET rearrangement in pleural effusion (PE) and ascitic effusion (AE)-derived organoids of P-61.

(I) Dose-effect curve of LCOs derived from the PE and AE of P-61.




Figure 6. Proteomic profiles of pleural fluid-derived organoids indicated drug resistance mechanisms

(A) PCA plot of the protein expression levels of different groups. The control group is shown in blue. The combination group, in which the LCOs were treated with both osimertinib and BLU-667, is shown in green. The groups treated with osimertinib (Osi) and BLU-667 alone are shown in purple and yellow, respectively. (B) Volcano plots of differentially expressed proteins (DEPs) are shown for the osimertinib versus control group. (C) Volcano plot of DEPs is shown for the BLU-667 versus control group. (D) Volcano plot of DEPs is shown for the combo versus control group. (E) Expression levels of the caspase family in osimertinib versus control (orange), BLU-667 versus control (blue), and combo versus control (light purple). (F) An overview of the alteration of the signaling cascade of EGFR and RET; arrows indicate the trend of the expression of related proteins. (G) Changes in the expression levels of key proteins among the osimertinib versus control, BLU-667 versus control, and combo versus control groups. See also Figure S6.

therapy and chemotherapy for the treatment of patients with advanced lung cancer. A total of 162 organoids, most of which were derived from MSE samples, were established in our cohort. The success rate of tissue-derived and MSE-derived organoids was 57.8% (30 of 52) and 81.4% (132 of 162), implying that MSE could provide an opportunity to bridge this gap in the success rate. Tumor cell count is often insufficient in organoid cultures obtained from core needle biopsies and lymph node resections. Furthermore, one limitation of models obtained from surgical and biopsy samples is the overgrowth of normal airway epithelial cells.⁵⁰ However, an MSE consists primarily of tumor cells rather than non-malignant epithelial or mesothelial cells and can be obtained by a relatively minimally invasive manner.⁵¹

Therefore, LCOs derived from MSE tend to be purer tumor organoids, allowing these models to be excellent candidates for DST. LCOs derived from either tissue or MSE samples faithfully reflected the pathological and molecular characteristics of the original tumor, and these results provided a reliable basis for the subsequent DST. The LCO-DST results are highly consistent with the clinical response to therapy, and the method is promising as a significant prediction tool for use in personalized medicine to build individualized treatment regimens for lung cancer.

Whether LCOs derived from MSEs represent the entire tumor profile is a critical challenge in the application of this method. Previous studies have shown that the accordance of genetics profile between MSE liquid biopsy and tissue biopsy was higher

than 80%.⁵² Thus, in some cases, MSEs may replace tissue biopsy in diagnostic occasions. However, in this study, the LCO-DST results of P-17 suggesting sensitive to osimertinib failed to predict the over clinical response (PR in the lung, while brain metastases PD), and the mixed response to osimertinib may be a confounding factor. The results of several patients revealed that metastatic lesion biopsy derived LCOs can predict the clinical response of local lesions to therapeutic agents, but sometimes cannot give an overall prediction because of heterogeneity.

In the context of modern precision medicine, NGS presents good analytical validity to detect clonally dominant alterations.⁵³ It has recently been applied in clinics with the aim of identifying targetable alterations. However, the emergence of drug resistance is the greatest challenge in targeted therapy.⁵⁴ In this context, it is important to identify a preclinical model suitable for new drug research in lung cancer. For instance, patients P-59 and P-70, who both exhibited EGFR-TKI-resistant disease, did not show any resistant mutations. Thus, the DST results are critical for the selection of a more effective treatment regimen.

Continuous sampling was performed for some patients in this cohort. Genetic features and drug responses in MSE and LCOs exhibited high concordance. These results indicated that the genetic profile and LCO-DST provided a stable readout, which was highly correlated with clinical efficacy. However, fewer living cells could be collected from the samples obtained during the later dates, which may have affected the success of LCO cultures. Therefore, collecting effusions during the first few days is recommended. Moreover, because of heterogeneity, the drug test assays may show different results from LCOs derived from samples collected at different dates from the same patient. Another finding of this study is that previous treatments cannot be accurately detected by LCOs, although this may not affect the real-world application of LCO-DST, which is to detect the sensitivity of unused drugs, as in this study.

As a functional model that can include the multi-omics characteristics of the original tumor and simulate drug sensitivity in patients, tumor organoids can also be applied in the development of novel drugs as an *in vitro* tumor replacement.⁵⁵ In this study, proteomics analysis was applied to analyze the molecular landscape of combinational therapies and present the molecular details that explain the clinical efficacy of combination treatment. Tumor organoids have several unique advantages: they are representative of the morphological and molecular characteristics of the original tumor and can partially simulate the physiological and drug sensitivity characteristics of the original tumor.^{4,38,56–60} Further, they exhibit rapid proliferation, a short culture cycle, and a high success rate of culture when drug sensitivity tests are performed. As mentioned above, the results of LCO-DST can guide clinical treatment regimens.

In the clinical use of anti-cancer agents, appropriate drugs should be selected according to the specific characteristics of each patient, such as the genetic mutations involved and other factors. The formulation of the drug sensitivity scheme followed the principles of clinical drug use to maximize the results of LCO drug sensitivity to guide the subsequent clinical diagnosis and treatment of patients. Our studies showed that the concordance for overall consistency of drug sensitivity with the clinical

response reached 83.33%. A certain consistency exists between DST and clinical efficacy, which was validated in our cohort. For instance, the results of LCO-DST of a patient reflected the fact that the dual-targeted drugs showed high tumor control rates, which was later confirmed during the clinical treatment. In conclusion, our study gave an overview of the applications of LCO-DST to predict therapeutic response in advanced lung cancer and found the LCO-DST a potential in precision medicine, further research can focus on the standardization of the approaches, such as large-scale clinical trials, to define the precise cutoff values or other perimeters in different types of therapeutic agents.

Limitations of the study

The major limitation of this study was the enrolled cohort. As a real-world study, it did not have a designed enrollment plan, and the genomic background and treatment regimen of the patients in our cohort varied. Small number of samples included for drug sensitivity analyses and inconsistent drug regimens in three groups except for osimertinib group also account for our study's limitations in many other regimens, the cutoff values of IC₅₀ of the effective and resistant groups were not yet defined. Moreover, the drug screening panel differed among the patients. Furthermore, many similar studies have focused on the long-term culture of LCOs and the establishment of living biobanks. In this study, to evaluate LCO-DST as a translational medicine approach, most organoids in our cohort were cultured and tested within a short period of time; therefore, not all organoids underwent genomic and pathological analyses. For similar reasons, not all organoids could be used in intensive investigation such as proteomics analysis and further biochemical analysis. In terms of proteomics, a further limitation is that all LCOs were used for LC-MS/MS tests, and there were insufficient samples for validation of the DEPs such as those in the Hippo pathway. As *EGFR* mutation combined with *RET* amplification is a rare genotype, no patient could be enrolled for validation. Owing to these limitations, this study cannot be classified as a "clinical trial." Nonetheless, this study reflects the real application of organoid technology in precision therapy for various subtypes of lung cancer and lays a foundation for further clinical trials.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
- METHOD DETAILS
 - Patient sample collection and processing
 - LCO cultures
 - Histology and immunohistochemistry
 - Fluorescence *in situ* hybridization
 - DNA extraction

- Next-generation sequencing library preparation and capture-based targeted sequencing
- Sequence data analysis
- Drug treatments and sensitivity tests
- Proteomics
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.xcrm.2022.100911>.

ACKNOWLEDGMENTS

We thank all patients who participated in this study as well as their families. We thank Prof. Chuxia Deng from University of Macau for the helpful discussions. We also thank Burning Rock Biotech, Nanjing Geneseeq Technology Inc., and Tongshu Biotechnology Co., LTD. for their help with data analysis. The authors also thank Accurate International Biotechnology Co. for their assistance with the organoid techniques. We also thank Shanghai Applied Protein Technology Co. for the help with proteomics analysis. This study was supported by the High-level Hospital Construction Project (grant no. DFJH201809 to J.J.Y.); the National Natural Science Foundation of China (grant no. 81972164 to J.J.Y.); the Natural Science Foundation of Guangdong Province (grant no. 2019A151010931 to J.J.Y.); and the Key Lab System Project of Guangdong Science and Technology Department – Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer (grant no. 2017B030314120 to Y.L.W.).

AUTHOR CONTRIBUTIONS

Conceptualization, J.J.Y., Y.L.W., and H.J.C.; methodology, Z.X.C., Y.F.L., and C.X.; investigation, W.F.L., Q.Y.G., S.L.Z., J.W.S., and Y.Q.C.; writing - original draft, H.M.W., C.Y.Z., K.C.P., J.W.S., and Z.X.C.; writing - review & editing, X.C.Z. and J.J.Y.; visualization, H.M.W., C.Y.Z., and K.C.P.; funding acquisition, J.J.Y.; resources, Q.Y.G., S.L.Z., J.W.S.; supervision, Q.Z., C.R.X., Z.W., and J.S.; validation, Q.Z., C.R.X., Z.W., and J.S.; formal analysis, H.H.Y.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: May 23, 2022

Revised: October 23, 2022

Accepted: December 22, 2022

Published: January 18, 2023

REFERENCES

1. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* *71*, 209–249. <https://doi.org/10.3322/caac.21660>.
2. Wang, N., Mengersen, K., Tong, S., Kimlin, M., Zhou, M., Wang, L., and Hu, W. (2019). Lung cancer mortality in China: spatial and temporal trends among subpopulations. *Chest* *156*, 972–983. <https://doi.org/10.1016/j.chest.2019.07.023>.
3. Porcel, J.M., Gasol, A., Bielsa, S., Civit, C., Light, R.W., and Salud, A. (2015). Clinical features and survival of lung cancer patients with pleural effusions. *Respirology* *20*, 654–659. <https://doi.org/10.1111/resp.12496>.
4. Pauli, C., Hopkins, B.D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017). Personalized in vitro and in vivo cancer models to guide precision medicine. *Cancer Discov.* *7*, 462–477. <https://doi.org/10.1158/2159-8290.CD-16-1154>.
5. Wu, L., Wang, Y., Xu, X., Liu, Y., Lin, B., Zhang, M., Zhang, J., Wan, S., Yang, C., and Tan, W. (2021). Aptamer-based detection of circulating targets for precision medicine. *Chem. Rev.* *121*, 12035–12105. <https://doi.org/10.1021/acs.chemrev.0c01140>.
6. Hahn, W.C., Bader, J.S., Braun, T.P., Califano, A., Clemons, P.A., Druker, B.J., Ewald, A.J., Fu, H., Jagu, S., Kemp, C.J., et al. (2021). An expanded universe of cancer targets. *Cell* *184*, 1142–1155. <https://doi.org/10.1016/j.cell.2021.02.020>.
7. Wu, Y.L., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol.* *18*, 1454–1466. [https://doi.org/10.1016/S1470-2045\(17\)30608-3](https://doi.org/10.1016/S1470-2045(17)30608-3).
8. Arbour, K.C., and Riely, G.J. (2019). Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. *JAMA* *322*, 764–774. <https://doi.org/10.1001/jama.2019.11058>.
9. Cobain, E.F., Wu, Y.M., Vats, P., Chugh, R., Worden, F., Smith, D.C., Schuetze, S.M., Zalupski, M.M., Sahai, V., Alva, A., et al. (2021). Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors. *JAMA Oncol.* *7*, 525–533. <https://doi.org/10.1001/jamaoncol.2020.7987>.
10. Liu, X., Lu, Y., Zhu, G., Lei, Y., Zheng, L., Qin, H., Tang, C., Ellison, G., McCormack, R., and Ji, Q. (2013). The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. *J. Clin. Pathol.* *66*, 1065–1069. <https://doi.org/10.1136/jclinpath-2013-201728>.
11. Cai, G., Wong, R., Chheng, D., Levy, G.H., Gettinger, S.N., Herbst, R.S., Puchalski, J.T., Homer, R.J., and Hui, P. (2013). Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. *Cancer Cytopathol.* *121*, 500–507. <https://doi.org/10.1002/cncy.21288>.
12. Wang, W., Tang, Y., Li, J., Jiang, L., Jiang, Y., and Su, X. (2015). Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. *Cancer Cytopathol.* *123*, 117–122. <https://doi.org/10.1002/cncy.21510>.
13. Sacher, A.G., Dahlberg, S.E., Heng, J., Mach, S., Jänne, P.A., and Oxnard, G.R. (2016). Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. *JAMA Oncol.* *2*, 313–320. <https://doi.org/10.1001/jamaoncol.2015.4482>.
14. Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., and Wong, K.K. (2014). Non-small-cell lung cancers: a heterogeneous set of diseases. *Nat. Rev. Cancer* *14*, 535–546. <https://doi.org/10.1038/nrc3775>.
15. Byeon, S., Lee, B., Park, W.Y., Choi, Y.L., Jung, H.A., Sun, J.M., Ahn, J.S., Ahn, M.J., Park, K., and Lee, S.H. (2020). Benefit of targeted DNA sequencing in advanced non-small-cell lung cancer patients without EGFR and ALK alterations on conventional tests. *Clin. Lung Cancer* *21*, e182–e190. <https://doi.org/10.1016/j.clcc.2019.11.006>.
16. Lin, A., Giuliano, C.J., Palladino, A., John, K.M., Abramowicz, C., Yuan, M.L., Sausville, E.L., Lukow, D.A., Liu, L., Chait, A.R., et al. (2019). Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. *Sci. Transl. Med.* *11*, eaaw8412. <https://doi.org/10.1126/scitranslmed.aaw8412>.
17. Stinchcombe, T.E. (2016). The use of EGFR tyrosine kinase inhibitors in EGFR wild-type non-small-cell lung cancer. *Curr. Treat. Options Oncol.* *17*, 18. <https://doi.org/10.1007/s11864-016-0394-4>.
18. Cartwright, D., Roxburgh, P., Stanley, B., Brown, J., McLaren, A., Coulter, S., Forte, C., and Glasspool, R. (2020). 510 Niraparib outcomes in brca wild-type platinum sensitive recurrent ovarian cancer: a comparison of real-world data to the nova trial. *Int. J. Gynecol. Cancer* *30*, A85–A86. <https://doi.org/10.1136/ijgc-2020-ESGO.146>.

19. Gazdar, A.F., Girard, L., Lockwood, W.W., Lam, W.L., and Minna, J.D. (2010). Lung cancer cell lines as tools for biomedical discovery and research. *J. Natl. Cancer Inst.* *102*, 1310–1321. <https://doi.org/10.1093/jnci/djq279>.
20. Pan, Y., Han, H., Labbe, K.E., Zhang, H., and Wong, K.K. (2021). Recent advances in preclinical models for lung squamous cell carcinoma. *Oncogene* *40*, 2817–2829. <https://doi.org/10.1038/s41388-021-01723-7>.
21. de Witte, C.J., Espejo Valle-Inclan, J., Hami, N., Löhmußaar, K., Kopper, O., Vreuls, C.P.H., Jonges, G.N., van Diest, P., Nguyen, L., Clevers, H., et al. (2020). Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and inpatient drug responses. *Cell Rep.* *31*, 107762. <https://doi.org/10.1016/j.celrep.2020.107762>.
22. Wang, D., Pham, N.A., Tong, J., Sakashita, S., Allo, G., Kim, L., Yanagawa, N., Raghavan, V., Wei, Y., To, C., et al. (2017). Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. *Int. J. Cancer* *140*, 662–673. <https://doi.org/10.1002/ijc.30472>.
23. Meehan, T.F., Conte, N., Goldstein, T., Inghirami, G., Murakami, M.A., Brabetz, S., Gu, Z., Wisner, J.A., Dunn, P., Begley, D.A., et al. (2017). PDX-MI: minimal information for patient-derived tumor xenograft models. *Cancer Res.* *77*, e62–e66. <https://doi.org/10.1158/0008-5472.CAN-17-0582>.
24. Nagle, P.W., Plukker, J.T.M., Muijs, C.T., van Luijk, P., and Coppes, R.P. (2018). Patient-derived tumor organoids for prediction of cancer treatment response. *Semin. Cancer Biol.* *53*, 258–264. <https://doi.org/10.1016/j.semcancer.2018.06.005>.
25. Jung, J., Seol, H.S., and Chang, S. (2018). The generation and application of patient-derived xenograft model for cancer research. *Cancer Res. Treat.* *50*, 1–10. <https://doi.org/10.4143/crt.2017.307>.
26. Becher, O.J., and Holland, E.C. (2006). Genetically engineered models have advantages over xenografts for preclinical studies. *Cancer Res.* *66*, 3355–3358. <https://doi.org/10.1158/0008-5472.CAN-05-3827>.
27. Chen, H., Gotimer, K., De Souza, C., Tepper, C.G., Karnezis, A.N., Leiserowitz, G.S., Chien, J., and Smith, L.H. (2020). Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. *Gynecol. Oncol.* *157*, 783–792. <https://doi.org/10.1016/j.ygyno.2020.03.026>.
28. Hill, S.J., Decker, B., Roberts, E.A., Horowitz, N.S., Muto, M.G., Worley, M.J., Jr., Feltmate, C.M., Nucci, M.R., Swisher, E.M., Nguyen, H., et al. (2018). Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. *Cancer Discov.* *8*, 1404–1421. <https://doi.org/10.1158/2159-8290.CD-18-0474>.
29. Fatehullah, A., Tan, S.H., and Barker, N. (2016). Organoids as an in vitro model of human development and disease. *Nat. Cell Biol.* *18*, 246–254. <https://doi.org/10.1038/ncb3312>.
30. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015). Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell* *161*, 933–945. <https://doi.org/10.1016/j.cell.2015.03.053>.
31. Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science* *359*, 920–926. <https://doi.org/10.1126/science.aao2774>.
32. Tamura, H., Higa, A., Hoshi, H., Hiyaama, G., Takahashi, N., Ryufuku, M., Morisawa, G., Yanagisawa, Y., Ito, E., Imai, J.I., et al. (2018). Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. *Oncol. Rep.* *40*, 635–646. <https://doi.org/10.3892/or.2018.6501>.
33. Zhao, J.P., Hu, Y., Du, R.H., Chen, Z.S., Jin, Y., Zhou, M., Zhang, J., Qu, J.M., and Cao, B. (2020). [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia]. *Zhonghua Jiehe He Huxi Zazhi* *43*, E007. <https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0007>.
34. Holokai, L., Chakrabarti, J., Lundy, J., Croagh, D., Adhikary, P., Richards, S.S., Woodson, C., Steele, N., Kuester, R., Scott, A., et al. (2020). Murine- and human-derived autologous organoid/immune cell Co-cultures as preclinical models of pancreatic ductal adenocarcinoma. *Cancers* *12*, 3816. <https://doi.org/10.3390/cancers12123816>.
35. Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I.C., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. (2015). Organoid models of human and mouse ductal pancreatic cancer. *Cell* *160*, 324–338. <https://doi.org/10.1016/j.cell.2014.12.021>.
36. Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A.V., Wind, K., Gracanin, A., Begthel, H., et al. (2018). A living biobank of breast cancer organoids captures disease heterogeneity. *Cell* *172*, 373–386.e10. <https://doi.org/10.1016/j.cell.2017.11.010>.
37. Chen, J.H., Chu, X.P., Zhang, J.T., Nie, Q., Tang, W.F., Su, J., Yan, H.H., Zheng, H.P., Chen, Z.X., Chen, X., et al. (2020). Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. *Thorac. Cancer* *11*, 2279–2290. <https://doi.org/10.1111/1759-7714.13542>.
38. Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., Martins-Filho, S.N., Raghavan, V., Li, Q., Mer, A.S., et al. (2020). Organoid cultures as preclinical models of non-small cell lung cancer. *Clin. Cancer Res.* *26*, 1162–1174. <https://doi.org/10.1158/1078-0432.CCR-19-1376>.
39. Li, Z., Qian, Y., Li, W., Liu, L., Yu, L., Liu, X., Wu, G., Wang, Y., Luo, W., Fang, F., et al. (2020). Human lung adenocarcinoma-derived organoid models for drug screening. *iScience* *23*, 101411. <https://doi.org/10.1016/j.isci.2020.101411>.
40. Hu, Y., Sui, X., Song, F., Li, Y., Li, K., Chen, Z., Yang, F., Chen, X., Zhang, Y., Wang, X., et al. (2021). Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. *Nat. Commun.* *12*, 2581. <https://doi.org/10.1038/s41467-021-22676-1>.
41. Ding, S., Hsu, C., Wang, Z., Natesh, N.R., Millen, R., Negrete, M., Giroux, N., Rivera, G.O., Dohlman, A., Bose, S., et al. (2022). Patient-derived micro-organospheres enable clinical precision oncology. *Cell Stem Cell* *29*, 905–917.e6. <https://doi.org/10.1016/j.stem.2022.04.006>.
42. Kim, S.Y., Kim, S.M., Lim, S., Lee, J.Y., Choi, S.J., Yang, S.D., Yun, M.R., Kim, C.G., Gu, S.R., Park, C., et al. (2021). Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. *Clin. Cancer Res.* *27*, 4397–4409. <https://doi.org/10.1158/1078-0432.CCR-20-5026>.
43. Lee, D., Kim, Y., and Chung, C. (2021). Scientific validation and clinical application of lung cancer organoids. *Cells* *10*. <https://doi.org/10.3390/cells10113012>.
44. Kim, M., Mun, H., Sung, C.O., Cho, E.J., Jeon, H.-J., Chun, S.-M., Jung, D.J., Shin, T.H., Jeong, G.S., Kim, D.K., et al. (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. *Nat. Commun.* *10*, 3991.
45. Terry, J., Leung, S., Laskin, J., Leslie, K.O., Gown, A.M., and Ionescu, D.N. (2010). Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. *Am. J. Surg. Pathol.* *34*, 1805–1811. <https://doi.org/10.1097/PAS.0b013e3181f7dae3>.
46. Tannock, I.F., and Hickman, J.A. (2016). Limits to personalized cancer medicine. *N. Engl. J. Med.* *375*, 1289–1294.
47. Vargas, A.J., and Harris, C.C. (2016). Biomarker development in the precision medicine era: lung cancer as a case study. *Nat. Rev. Cancer* *16*, 525–537.
48. Wu, C.G., Chiovaro, F., Curioni-Fontecedro, A., Casanova, R., and Soltermann, A. (2020). In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening. *J. Transl. Med.* *18*, 163. <https://doi.org/10.1186/s12967-020-02331-x>.
49. Li, J., Xu, H., Zhang, L., Song, L., Feng, D., Peng, X., Wu, M., Zou, Y., Wang, B., Zhan, L., et al. (2019). Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.

- J. Cancer Res. Clin. Oncol. *145*, 2637–2647. <https://doi.org/10.1007/s00432-019-03004-z>.
50. Dijkstra, K.K., Monkhorst, K., Schipper, L.J., Hartemink, K.J., Smit, E.F., Kaing, S., de Groot, R., Wolkers, M.C., Clevers, H., Cuppen, E., and Voest, E.E. (2020). Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. *Cell Rep.* *31*, 107588. <https://doi.org/10.1016/j.celrep.2020.107588>.
 51. Carneiro, F.P., Muniz-Junqueira, M.I., Pittella-Silva, F., Carneiro, M.d.V., Takano, G.H.S., Vianna, L.M.d.S., De Andrade, L.B., De Castro, T.M.M.L., Peres, I., Dos Santos Borges, T.K., et al. (2017). A panel of markers for identification of malignant and non-malignant cells in culture from effusions. *Oncol. Rep.* *38*, 3538–3544. <https://doi.org/10.3892/or.2017.6022>.
 52. Jiao, X.D., Ding, L.R., Zhang, C.T., Qin, B.D., Liu, K., Jiang, L.P., Wang, X., Lv, L.T., Ding, H., Li, D.M., et al. (2021). Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma. *Transl. Lung Cancer Res.* *10*, 3236–3250. <https://doi.org/10.21037/tlcr-21-543>.
 53. Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., Schnall-Levin, M., White, J., Sanford, E.M., An, P., et al. (2013). Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat. Biotechnol.* *31*, 1023–1031. <https://doi.org/10.1038/nbt.2696>.
 54. Lim, Z.F., and Ma, P.C. (2019). Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. *J. Hematol. Oncol.* *12*, 134. <https://doi.org/10.1186/s13045-019-0818-2>.
 55. Sato, T., Stange, D.E., Ferrante, M., Vries, R.G.J., Van Es, J.H., Van den Brink, S., Van Houdt, W.J., Pronk, A., Van Gorp, J., Siersema, P.D., and Clevers, H. (2011). Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* *141*, 1762–1772. <https://doi.org/10.1053/j.gastro.2011.07.050>.
 56. Weeber, F., van de Wetering, M., Hoogstraat, M., Dijkstra, K.K., Krijgsman, O., Kuilman, T., Gadellaa-van Hooijdonk, C.G.M., van der Velden, D.L., Peeper, D.S., Cuppen, E.P.J.G., et al. (2015). Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. *Proc. Natl. Acad. Sci. USA* *112*, 13308–13311. <https://doi.org/10.1073/pnas.1516689112>.
 57. Huang, L., Holtzinger, A., Jagan, I., BeGora, M., Lohse, I., Ngai, N., Nostro, C., Wang, R., Muthuswamy, L.B., Crawford, H.C., et al. (2015). Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. *Nat. Med.* *21*, 1364–1371. <https://doi.org/10.1038/nm.3973>.
 58. Chua, C.W., Shibata, M., Lei, M., Toivanen, R., Barlow, L.J., Bergren, S.K., Badani, K.K., McKiernan, J.M., Benson, M.C., Hibshoosh, H., and Shen, M.M. (2014). Single luminal epithelial progenitors can generate prostate organoids in culture. *Nat. Cell Biol.* *16*, 951–961. <https://doi.org/10.1038/ncb3047>.
 59. Mullenders, J., de Jongh, E., Brousalı, A., Roosen, M., Blom, J.P.A., Begthel, H., Korving, J., Jonges, T., Kranenburg, O., Meijer, R., and Clevers, H.C. (2019). Mouse and human urothelial cancer organoids: a tool for bladder cancer research. *Proc. Natl. Acad. Sci. USA* *116*, 4567–4574. <https://doi.org/10.1073/pnas.1803595116>.
 60. Roelofs, C., Holland, F., Redvers, R., Anderson, R.L., and Merino, D. (2019). Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer. *Biochem. Soc. Trans.* *47*, 109–117. <https://doi.org/10.1042/BST20180375>.
 61. Ma, J., Chen, T., Wu, S., Yang, C., Bai, M., Shu, K., Li, K., Zhang, G., Jin, Z., He, F., et al. (2019). iProX: an integrated proteome resource. *Nucleic Acids Res.* *47*, D1211–D1217. <https://doi.org/10.1093/nar/gky869>.
 62. Wu, D., Xie, Y., Jin, C., Qiu, J., Hou, T., Du, H., Chen, S., Xiang, J., Shi, X., and Liu, J. (2020). The landscape of kinase domain duplication in Chinese lung cancer patients. *Ann. Transl. Med.* *8*, 1642. <https://doi.org/10.21037/atm-20-7408>.
 63. Li, Y.S., Jiang, B.Y., Yang, J.J., Zhang, X.C., Zhang, Z., Ye, J.Y., Zhong, W.Z., Tu, H.Y., Chen, H.J., Wang, Z., et al. (2018). Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. *Ann. Oncol.* *29*, 945–952. <https://doi.org/10.1093/annonc/mdy009>.
 64. Jin, Y., Xue, Q., Shen, X., Zheng, Q., Chen, H., Zhou, X., and Li, Y. (2022). PD-L1 expression and comprehensive molecular profiling predict survival in non-small cell lung cancer: a real-world study of a large Chinese cohort. *Clin. Lung Cancer* *23*, 43–51. <https://doi.org/10.1016/j.clcc.2021.08.009>.
 65. Ding, R.B., Chen, P., Rajendran, B.K., Lyu, X., Wang, H., Bao, J., Zeng, J., Hao, W., Sun, H., Wong, A.H.H., et al. (2021). Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. *Nat. Commun.* *12*, 3046. <https://doi.org/10.1038/s41467-021-23379-3>.
 66. Wiśniewski, J.R., and Mann, M. (2012). Consecutive proteolytic digestion in an enzyme reactor increases depth of proteomic and phosphoproteomic analysis. *Anal. Chem.* *84*, 2631–2637. <https://doi.org/10.1021/ac300006b>.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or SOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit anti TTF-1	Abcam	Cat# ab133638;RRID: AB_2734144
Rabbit anti Napsin A	Abcam	Cat# ab129189; RRID:AB_11143020
Rabbit anti CK-7	Abcam	Cat# ab181598;RRID: AB_2783822
Rabbit anti P63	Abcam	Cat# ab124762; RRID: AB_10971840
Rabbit anti P40	Abcam	Cat# ab273135; RRID: AB_2927663
Rabbit anti CK5/6	Abcam	Cat# ab52635;RRID: AB_869890
Rabbit anti CD56	Abcam	Cat# ab220360; RRID: AB_2927664
Rabbit anti Synaptophysin	Abcam	Cat# ab32127; RRID: AB_2286949
Rabbit anti Chromogranin	Abcam	Cat# ab254322; RRID: AB_2910555
Rabbit anti EGF Receptor (L858R Mutant Specific) (43B2)	ewEast	Cat# 26082; RRID: AB_2629297
Goat Anti-Rabbit IgG H&L (HRP)	Abcam	Cat# ab205718;RRID: AB_2819160
Goat Anti-Mouse IgG H&L (HRP)	Abcam	Cat# ab205719;RRID: AB_2755049
Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)	Abcam	Cat# ab150077;RRID: AB_2630356
Biological samples		
Human tumor tissue samples	This study	N/A
Human effusion samples	This study	N/A
Chemicals, peptides, and recombinant proteins		
B27 supplement (-Vit A)	GIBCO	Cat# 17504044
N2 supplement	GIBCO	Cat# 17502048
GlutaMax	GIBCO (ThermoFisher)	Cat# 35050061
Wnt3A	Novoprotein	Cat# C06D
R-Spondin1	Novoprotein	Cat# CX83
Noggin	Novoprotein	Cat# CB89
EGF	Peprotech	Cat# AF-100-15
FGF-basic	Peprotech	Cat# 100-18C
Y27632	MCE	Cat# HY-10071
A83-01	Sigma-Aldrich	Cat# SML0788
DMEM/F12	GIBCO	Cat# 12634028
Green Chromogen	Leica	Cat# DC9913
BOND IHC polymer detection kit	Leica	Cat# DS9800
FBS	GIBCO	Cat# 10099141
PBS	Sangon	Cat# E607008-0500
HEPES	Sigma-Aldrich	Cat# H6147
HBSS	GIBCO	Cat# 14175095
Penicillin-Streptomycin	Sigma-Aldrich	Cat# V900929
Amphotericin B	GIBCO	Cat# 15290026
Cell recovery solution	Corning	Cat# 354253
Matrigel	Corning	Cat# 356231
DNase	Sigma-Aldrich	Cat# 11284932001
Collagenase/dispase	Roche	Cat# 10269638001
BOND IHC polymer detection kit	Leica	Cat# DS9800

(Continued on next page)

Continued		
REAGENT or SOURCE	SOURCE	IDENTIFIER
Afatinib	MCE	Cat# HY-10261
Osimertinib	MCE	Cat# HY-15772
Erlotinib	MCE	Cat# HY-50896
Gefitinib	MCE	Cat# HY-50895
Dacomitinib	MCE	Cat# HY-13272
Almonertinib	MCE	Cat# HY-112823
Icotinib	MCE	Cat# HY-15164A
SAF-189s	Fochon Pharmaceuticals	N/A
Crizotinib	MCE	Cat# HY-50878
Alectinib	MCE	Cat# HY-13011
Ceritinib	MCE	Cat# HY-15656
Brigatinib	MCE	Cat# HY-12857
Lorlatinib	MCE	Cat# HY-12215
Entrectinib	MCE	Cat# HY-12678
Dabrafenib	MCE	Cat# HY-14660
Pyrotinib	MCE	Cat# HY-104065
Larotrectinib	MCE	Cat# HY-12866
Savolitinib	MCE	Cat# HY-15959
Bozitinib	MCE	Cat# HY-125017
BLU667	MCE	Cat# HY-112301
Docetaxel	MCE	Cat# HY-B0011
Paclitaxel	MCE	Cat# HY-B0015
Gemcitabine	MCE	Cat# HY-17026
Etoposide	MCE	Cat# HY-13629
Pemetrexed	MCE	Cat# HY-10820
Cisplatin	MCE	Cat# HY-17394
Carboplatin	MCE	Cat# HY-17393
Irinotecan	MCE	Cat# HY-16562
Experimental models:Organisms/Strains		
Human lung cancer organoid samples	This study	N/A
Software and algorithms		
R	R Development Core Team, 2008	https://www.r-project.org/
Critical commercial assays		
CellTiter-Glo® 3D Cell Viability Assay	Promega	Cat# G9681
Deposited data		
DNA sequencing	This paper	National Genomics Data Center (HRA003231)
LC-MS/MS	This paper	ProteomeXchange Consortium (PXD037076)
Others		
Cytation 5 Cell Imaging Multimode Reader	Agilent	Cat# BTCYT5M
Fluorescence microscope	Olympus	Cat# 29560
BOND-III automated stainer	Leica	Cat# 22.2201

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jin-Ji Yang (yangjinji@gdph.org.cn).

Materials availability

This study did not generate new unique reagents.

Data and code availability

- The next-generation DNA sequencing dataset generated during this study is available at the National Genomics Data Center: HRA003231 (URL: <https://ngdc.cncb.ac.cn>). The mass spectrometry proteomics data reported in this paper have been deposited to the ProteomeXchange Consortium: PXD037076 (<http://proteomecentral.proteomexchange.org>) via iProx partner repository⁶¹.
- This paper does not report the original code.
- Any additional information required to reanalyze the data reported in this work paper is available from the [lead contact](#) upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Primary or metastatic tumor tissues were obtained from patients with advanced lung cancer by performing fine-needle aspiration or surgically resected biopsies at Guangdong Provincial People's Hospital. Malignant effusion samples were also collected. The collection of patient data and biospecimens for lung cancer organoid (LCO) culture, drug tests, and further studies has been performed according to the guidelines of Research Ethics Committee of Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences (Ethics project number: No.GDREC2019323H), following both national and local laws. Written informed consent was also obtained from all patients. The main inclusion criteria were patients with clinically locally advanced or metastatic lung cancer, aged 18 years or older, with fresh tissues available through either biopsy or surgical resection of the primary or metastatic lesions, and with malignant effusion samples collected using a sterile drainage bag. Clinical information is available in [Table S1](#). Drug sensitivity tests were performed after the generation of sufficient LCOs. However, only patients with concurrent or subsequent clinical drug response evaluations, which were consistent with the LCO-based drug test results, were enrolled in the observational clinical research.

METHOD DETAILS

Patient sample collection and processing

The primary inclusion criteria were patients with clinically locally advanced or metastatic lung cancer, aged 18 years or older, with fresh tissues available from either biopsy or surgical resection of the primary or metastatic lesions, and with malignant effusion samples collected using a sterile drainage bag. Drug sensitivity tests were performed after generating sufficient LCOs. However, only patients with concurrent or subsequent clinical drug response evaluations, consistent with the LCO-based drug test results, were enrolled in the observational clinical research.

Primary or metastatic tumor tissues were obtained from patients with advanced lung cancer by performing fine-needle aspiration or surgically resected biopsies at Guangdong Provincial People's Hospital. Malignant effusion samples were also collected. Written informed consent was obtained from all patients. The research protocol was approved by the Research Ethics Committee of the Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences (Guangzhou, China). The samples were diagnosed based on pathological assessment.

LCO cultures

Patient-derived LCO cultures were obtained as previously described.³⁷ MSE samples (200–1000 mL) were obtained by thoracentesis and collected aseptically in heparinized (10 U/mL) sterile bottles or bags. These were subsequently transferred to the laboratory on ice for further processing within 4 h. Samples were centrifuged at 300 ×g for 5 min at 4°C, and the cell pellets were resuspended in LCO medium (LCOM, DMEM/F12, supplied with 20 ng/mL bFGF, 50 ng/mL human EGF, N2, B27, GlutaMAX, 10 μM Y-27632, and 1% penicillin-streptomycin, Gibco, New York, NY, USA). For the tumor tissue samples, tumor fragments were generated using sterilized ophthalmic scissors, sized approximately 1 mm³. These were suspended in cold Hank's Balanced Salt Solution (HBSS) with antibiotics and transported to the laboratory on ice within 1 h of resection. After washing thrice with cold HBSS containing antibiotics and sectioning with sterile blades, the samples were incubated in DMEM/F12 supplemented with 0.001% DNase, 1 mg/mL collagenase/dispase, penicillin-streptomycin, and 0.5 mg/mL amphotericin B at 37°C for 2 h with gentle agitation and intermittent resuspension. The digested tissue suspension was then titrated via pipetting and passed through a 70 μm filter.

The cell suspension generated from either MSE or tissue samples was centrifuged at 112 rpm for 3 min. The pellet was then resuspended in LCOM. Thereafter, 200 μL Matrigel (Corning, New York, NY, USA) was added to 100 μL of the cell suspension to establish organoids, and the resulting suspension was allowed to solidify upside-down in pre-warmed 6-well culture plates (Corning) at 37°C for 30 min. After gelation, 3 mL LCOM was added to each well. The medium was changed every two to three days.

Histology and immunohistochemistry

Organoids and their corresponding parental tumors were fixed in 4% paraformaldehyde, followed by paraffin embedding, sectioning, deparaffinization, dehydration, and hematoxylin and eosin staining. Immunohistochemistry (IHC) was performed using antibodies targeting the thyroid transcription factor (TTF-1), Cytokeratin 7 (CK7), and Napsin A for ADC; Cytokeratin 5/6 (CK5/6), P40, and P63 for SCC; TTF-1, synaptophysin (Syn), chromogranin A (CgA), and CD56 for SCLC. Green Chromogen and the BOND IHC polymer detection kit were used for color development. The IHC staining was performed using the BOND-III automated stainer (Leica, Wetzlar, Germany). Images were captured using the IX73 microscope (Olympus, Tokyo, Japan).

Fluorescence *in situ* hybridization

Dual-color fluorescence *in situ* hybridization (FISH) was performed using the MET probe, labeled with spectrum red, and the chromosome 17 specific centromere (D17Z1) probe, labeled with spectrum green, on sections cut from the same block. Deparaffinization, *in situ* hybridization, and staining were performed using the PathVysion kit (Abbott-Vysis Lab, Abbott Park, IL, USA). Fluorescent signals in at least 60 non-overlapping interphase nuclei with intact morphology were scored using a Zeiss Axioplan 2 microscope with a $\times 100$ planar objective using a triple band-pass filter permissive to blue, green, and red colors.

FISH for RET was performed using the ZytoLight SPEC RET Dual-Color Break Apart Probe Kit (CliniSciences, Montrouge, France). At least 100 tumor nuclei were analyzed, and a case was considered positive when the number of neoplastic nuclei with a split signal or with a single 3' signal was above a minimum of 20% of the observed neoplastic nuclei.

DNA extraction

DNA was extracted from tumor tissues and effusion-derived NSCLC organoids (also known as patient-derived LCOs) using the QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA, USA) and the QIAamp DNA kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Cell-free DNA was extracted from effusion samples using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. The concentration of DNA was measured with the Qubit 2.0 Fluorometer with the Qubit double-stranded DNA assay kit (Life Technologies, Carlsbad, CA, USA).

Next-generation sequencing library preparation and capture-based targeted sequencing

DNA extracted from the tumor, effusion, and LCO samples was fragmented using the Covaris M220 focused ultrasonicator (Covaris, Inc., Woburn, MA, USA) or Bioruptor ultrasonicator (diagenode sa, Inc., Seraing, Belgium), followed by end repair, phosphorylation, dA addition, and adaptor ligation for library construction. The samples were subsequently subjected to capture-based targeted sequencing using a panel of 520, 425, 168, or 139 cancer-related genes (panels of 520 or 168 belongs to Burning Rock Biotech, Guangzhou, China, while panels of 425 or 139 belongs to Nanjing Geneseeq Technology Inc.). DNA was hybridized with capture probe baits, selected with magnetic beads, and amplified using PCR. A bioanalyzer high-sensitivity DNA assay was performed to assess the quality and size of the fragments. Indexed samples were sequenced on the Nextseq500 sequencer (Illumina, Inc., San Diego, CA, USA) or HiSeq 4000 sequencer (Illumina, Inc., San Diego, CA, USA) with paired-end reads.

Sequence data analysis

Raw sequencing data were preprocessed using Trimmomatic 0.36 for trimming adaptors and low-quality reads. Preprocessed sequencing data were then mapped to the human genome (hg19) using Burrows–Wheeler Aligner 0.7.10. Variant calling and annotation were performed using the GATK 3.2, MuTect, and VarScan. According to the ExAC, 1,000 Genomes, dbSNP, and ESP6500SI-V2 databases, variants with a population frequency over 0.1% were grouped as single nucleotide polymorphisms and excluded from further analysis. The remaining variants were annotated using ANNOVAR and SnpEff v3.6. Copy number variations (CNVs) and large genomic rearrangements (LGRs) were detected using in-house analysis scripts based on the depth of coverage data of capture intervals, as previously described.^{62,63} DNA translocation analysis was performed using both Tophat2 and Factera 1.4.3. The maximum allele frequency (maxAF) for each mutation was calculated.

Tumor mutation burden (TMB) was defined as somatic single nucleotide variants (SNVs) and small insertions and deletions (indels) located in the coding region and its 20 bp upstream/downstream regions. TMB was calculated using the following equation: $TMB = \frac{\text{Mutation count (except for CNVs and fusions)}}{\text{Coding region size}}$

Differences between the two groups were assessed using the two-tailed t-test or Mann–Whitney U test for continuous variables. Statistical significance was set at $p < 0.05$. The Pearson correlation coefficient was used to assess the correlation between tumor and LCO-based TMB. Bivariant sensitivity and positive predictive value in LCO samples were calculated when the genomic profile of effusion samples was used as a reference. All statistical analyses were performed using R 3.3.3.

Drug treatments and sensitivity tests

Treatments with anti-cancer drugs and sensitivity tests were performed as described previously,^{64,65} with some modifications. Briefly, organoids cultured for 1–2 weeks were harvested and dissociated using $1\times$ TrypLe (Gibco). The dissociated organoids were mixed in LCOM with Matrigel (Corning) (1:1 ratio) and transferred onto 384-well white plates. Approximately, 2000 cells were

seeded in each well. After gelation, 30 μ L LCOM was added to each well. The organoids were cultured for 48 h. Thereafter, a dilution series of each compound (10, 2.5, 0.625, 0.156, 0.039, and 0.0097 μ M) was dispensed using liquid-handling robots. The cell viability was assayed using 3D CellTiter-Glo (Promega, Madison, WI, USA) after 96 h of drug incubation. The plates were agitated for 30 min at RT prior to luminescence measurement. The IC₅₀ values were determined using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA).

Proteomics

Protein extraction and digestion for LC-MS/MS

LCOs were transferred into a 6-well plate (Corning), incubated for 7 days, and then treated using osimertinib (0.6 μ M), BLU-667 (1 μ M), and the combination of osimertinib and BLU-667 (0.6 μ M and 1 μ M, respectively). The organoids were harvested using the Cell Recovery Solution (Corning) and stored in liquid nitrogen until further use for protein extraction.

SDT (4% SDS, 100 mM Tris-HCl, 1 mM DTT, pH 7.6) buffer was used for sample lysis and protein extraction. The amount of protein was quantified using the BCA Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Protein digestion using trypsin was performed according to the filter-aided sample preparation (FASP) procedure described by Matthias Mann.⁶⁶ The digest peptides of each sample were desalted on C18 Cartridges [Empore™ SPE Cartridges C18 (standard density), bed I.D., 7 mm; volume, 3 mL; Sigma], concentrated using vacuum centrifugation, and reconstituted in 40 μ L of 0.1% (v/v) formic acid.

FASP digestion procedure

A total of 200 μ g of proteins for each sample were incorporated into 30 μ L SDT buffer (4% SDS, 100 mM DTT, 150 mM Tris-HCl, pH 8.0). The detergent, DTT, and other low-molecular-weight components were removed using the UA buffer (8 M urea, 150 mM Tris-HCl, pH 8.0) by repeated ultrafiltration (Microcon units, 10 kD). Subsequently, 100 μ L iodoacetamide (100 mM IAA in UA buffer) was added to block reduced cysteine residues, and the samples were incubated for 30 min in the dark. The filters were washed with 100 μ L UA buffer three times and then using 100 μ L of 25 mM NH₄HCO₃ buffer twice. Finally, the protein suspensions were digested using 4 μ g of trypsin (Promega) in 40 μ L of 25 mM NH₄HCO₃ buffer overnight at 37°C. The resulting peptides were collected as a filtrate. The peptides of each sample were desalted on C18 Cartridges [Empore™ SPE Cartridges C18 (standard density), bed I.D., 7 mm; volume, 3 mL; Sigma], concentrated by vacuum centrifugation, and reconstituted in 40 μ L of 0.1% (v/v) formic acid. The peptide content was estimated by UV light spectral density at 280 nm using an extinction coefficient of 1.1 of 0.1% (g/L) solution that was calculated based on the frequency of tryptophan and tyrosine in vertebrate proteins.

LC-MS/MS analysis

LC-MS/MS analysis was performed using the timsTOF Pro mass spectrometer (Bruker, USA) coupled to Nanoelute (Bruker Daltonics) for 60 min. The peptides were loaded onto a reverse-phase trap column (Thermo Scientific Acclaim PepMap100, 100 μ m*2 cm, nanoViper C18) connected to the C18-reversed-phase analytical column (Thermo Scientific Easy Column, 10 cm long, 75 μ m inner diameter, 3 μ m resin) in buffer A (0.1% formic acid) and separated at a linear gradient of buffer B (84% acetonitrile and 0.1% formic acid) at a flow rate of 300 nL/min controlled by IntelliFlow technology. The mass spectrometer was operated in positive ion mode. The mass spectrometer recorded ion mobility MS spectra over a mass range of *m/z* 100–1700 and 1/k0 of 0.6–1.6. Subsequently, 10 cycles of PASEF MS/MS were performed with a target intensity of 1.5k and a threshold of 2500. The active exclusion was enabled with a release time of 0.4 min.

Protein identification and quantification

The raw MS data for each sample were combined and searched using MaxQuant 1.5.3.17 software for identification and quantitation analysis.

Bioinformatic analysis of proteomics data

Cluster analysis of phosphorylated peptides. Cluster 3.0 (<http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm>) and Java Treeview software (URL: <http://jtreeview.sourceforge.net>) were used to perform hierarchical clustering analysis. The Euclidean distance algorithm for similarity measurement and average linkage clustering algorithm (clustering uses the centroids of the observations) for clustering were selected when performing hierarchical clustering. A heatmap is often presented as a visual aid, in addition to the dendrogram.

Gene ontology (GO) annotation. The protein sequences of the selected DEPs were locally searched using the NCBI BLAST + client software (ncbi-blast-2.2.28+-win32.exe) and InterProScan to find homologous sequences, GO terms were mapped, and sequences were annotated using the Blast2GO software (BioBam Bioinformatics, Valencia, Spain). The GO annotation results were plotted using R scripts.

Kyoto encyclopedia of genes and genomes (KEGG) annotation. Following the annotation steps, the studied proteins were BLASTed against the online KEGG database (<http://geneontology.org/>) to retrieve their KEGG orthology identifications and were subsequently mapped to KEGG pathways.

Enrichment analysis. Enrichment analysis was performed based on the Fisher exact test, considering all quantified proteins as the background dataset. The Benjamini–Hochberg correction for multiple testing was applied to adjust the derived p values. Only functional categories and pathways with p values under a threshold of 0.05 were considered significant.

QUANTIFICATION AND STATISTICAL ANALYSIS

The capability of LCO-DST to discriminate between clinically effective or resistant patients was determined using receiver operating characteristic analysis. The predictor was organoid sensitivity to osimertinib, chemotherapy, dual targeted therapy, and other targeted therapy treatment, which is the ratio of the ATP luminance value of treated organoids to that of untreated organoids on day 4 after treatment. The diagnostic performance of the LCOs in predicting the patients' clinical response to different treatments were evaluated based on area under the curve, sensitivity, specificity, and diagnostic accuracy.

Cell Reports Medicine, Volume 4

Supplemental information

**Using patient-derived organoids to predict
locally advanced or metastatic lung cancer
tumor response: A real-world study**

Han-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, Ze-Xin Chen, Jun-Wei Su, Yu-Fa Li, Wen-Feng Li, Qing-Yun Gao, Shi-Ling Zhang, Yu-Qing Chen, Qing Zhou, Cong Xu, Chong-Rui Xu, Zhen Wang, Jian Su, Hong-Hong Yan, Xu-Chao Zhang, Hua-Jun Chen, Yi-Long Wu, and Jin-Ji Yang




Figure S1. The success rate of LCO cultures in this study. Related to Figure 1A





Figure S2. Genomic profiling of LCO samples. Related to Figure 2A

(A). Somatic alterations MSE samples. (B). Somatic alterations detected from MSE-derived LCO samples.




Figure S3. Correlation between IC₅₀s of targeted drugs and tumor cell reduction rates. Related to Figure 3 (A). The concordance for drug sensitivity between clinical response and LCO samples. (B). Receiver operating characteristic (ROC) analysis of osimertinib, chemotherapy, dual-targeted therapy, and other targeted therapy groups LCO drug tests (C). Heatmap of LCO-DST IC₅₀ of P-103, P-100, P-97, and P-95. (D). Correlation between IC₅₀ of osimertinib and the percentage of tumor shrinkage. (E). Dose-effect curves of alectinib, lorlatinib, and crizotinib of LCOs derived from P-63.




Figure S4. Dynamic evolution of cell numbers and genetic alterations in LCOs and MSEs. Related to Figure 4A
 (A). Cell density of MSEs in different sampling times. (B). Somatic alterations detected from LCOs at different sampling times in four patients.





Figure S5. Evaluation of tumor markers and baseline immunofluorescence of P-60. Related to Figure 5
 (A). Alterations of CEA, CYF21-1, and NSE of P-60. (B). Immunofluorescence staining of MET and DAPI of LCOs derived from pericardial effusion and lymph node of P-60. Scale bar, 20 μm .




Figure S6. Pie chart showing cell locations and scatter plot of KEGG enrichments of differentially expressed proteins (DEPs) from different comparison groups. Related to Figure 6

(A). Cell locations of the osimertinib vs. control group. (B). Cell locations of the BLU-667 vs. control group. (C). Cell locations of the combo vs. control group. (D). KEGG enrichment of the osimertinib vs. control group. (E). KEGG enrichment of the BLU-667 vs. control group. (F). KEGG enrichment of the combo vs. control group.

Table S1. The list of lung cancer samples used for successful establishment of patient-derived organoids. Related to Figure 1A.

Case	Organoid ID	Gender	Age	ECOG		Pathology diagnosis	Site of sampling	Driver mutation detected by routine genetic testing or FISH	Treatment lines	Therapies after acquiring tumor specimens to generate organoids	Organoid IHC
				PS score	Stage						
P-1	P-1-O1T	F	55	1	IVB	ADC	Pleural tissue	NA	4	NA	NA
P-2	P-2-O1T	M	51	1	IVB	ADC	Lung tissue	NA	2	Osimeertinib	NA
P-3	P-3-O1E	M	50	1	IVB	ADC	Pericardial effusion	EGFR 19 del	3	EP	NA
P-3	P-3-O2T	M	50	1	IVB	SCLC	Paraspinal mass	NA	4	Nab-paclitaxel	NA
P-5	P-5-O1T	M	61	1	IVB	ADC	Lung tissue	NA	4	Docetaxel	NA
P-6	P-6-O1T	F	57	2	IVB	ADC	Lung tissue	NA	7	Osimeertinib+IP	NA
P-7	P-7-O1E	F	34	2	IVB	ADC	Pericardial effusion	Negative	2	NA	NA
P-8	P-8-O1T	F	80	1	IVB	ADC	Pleural mass	EGFR L858R	1	Osimeertinib	NA
P-9	P-9-O1T	M	56	1	IVB	ADC	Lung tissue	NA	2	PCB	NA
P-10	P-10-O1E	M	39	4	IVB	ADC	Pleural effusion	NA	2	NA	NA
P-10	P-10-O2T	M	39	4	IVB	ADC	Lung tissue	EGFR 19 del	2	NA	NA
P-11	P-11-O1T	F	57	2	IVB	ADC	Lung tissue	NA	6	Paclitaxel	NA
P-12	P-12-O1T	F	55	1	IVB	ADC	Supraclavicular lymph node	EGFR 19 del	2	Osimeertinib	NA
P-12	P-12-O2T	F	55	1	IVB	ADC	Supraclavicular lymph node	NA	3	PCB	NA
P-12	P-12-O3T	F	55	1	IVB	ADC	Axillary lymph node	EGFR 19 del; MET amplification	4	ABCP	CK7(+);TTF1(+);NapsinA(-)
P-13	P-13-O1E	F	77	1	IVA	ADC	Pleural effusion	NA	2	Beritinib + Bevacizumab	NA
P-14	P-14-O1E	F	75	2	IVB	ADC	Pleural effusion	MET 14 skipping	4	Anlotinib	NA
P-16	P-16-O1T	F	67	1	IVA	ADC	Supraclavicular lymph node	EGFR 19 del	3	PCB	NA
P-17	P-17-O1E	F	40	1	IVB	ADC	Pleural effusion	EGFR 19 del	1	Osimeertinib	NA
P-17	P-17-O2E	F	41	1	IVB	ADC	Pleural effusion	EGFR 19 del	2	Osimeertinib	NA
P-17	P-17-O3E	F	41	1	IVB	ADC	Pleural effusion	EGFR 19 del	2	Osimeertinib	NA
P-18	P-18-O1T	M	80	3	IVB	ADC	Supraclavicular lymph node	EGFR L858R;T790M	2	Osimeertinib	CK7(+);TTF1(+);NapsinA(+)
P-19	P-19-O1T	F	68	2	IVB	ADC	Paraspinal mass	NA	3	NA	NA
P-23	P-23-O1E	M	51	3	IVB	ADC	Pericardial effusion	NA	7	Afatinib+Cetuximab	NA
P-23	P-23-O2T	M	51	3	IVB	ADC	Lung tissue	EGFR L858R;EGFR L718Q;	7	Afatinib+Cetuximab	NA
P-24	P-24-O1T	M	65	1	IVA	ADC	Left adrenal puncture	NA	2	PCB	NA
P-25	P-25-O1E	F	32	1	IVB	ADC	Pleural effusion	CD74-ROS1 fusion, ROS1-intergenic fusion	3	PC	NA
P-27	P-27-O1E	M	55	3	IVB	ADC	Pericardial effusion	EML4-ALK fusion	3	Crizotinib	NA
P-28	P-28-O1E	M	41	1	IVB	ADC	Pleural effusion	CD74-ROS1 fusion	2	NA	NA
P-30	P-30-O1E	M	50	2	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M; RET fusion	4	Osimeertinib	NA
P-30	P-30-O2E	M	50	2	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M; RET fusion	4	Osimeertinib	NA
P-30	P-30-O3E	M	50	2	IVB	ADC	Pleural effusion	EGFR 19 del;T790M;FAM118A-NTRK1 fusion;RE	4	Osimeertinib	NA
P-32	P-32-O1T	F	69	1	IIIB	ADC	Lymph node	EGFR L858R;T790M	1	Osimeertinib	CK7(+);TTF1(-);NapsinA(+)
P-33	P-33-O1E	F	54	1	IVA	ADC	Pleural effusion	EML4-ALK fusion, ALK-C17orf75 fusion	1	Alectinib	CK7(+);TTF1(+);NapsinA(+)
P-33	P-33-O2T	F	54	1	IVA	ADC	Supraclavicular lymph node	EML4-ALK fusion	1	Alectinib	CK7(+);TTF1(+);NapsinA(+)
P-34	P-34-O1E	M	41	2	IVB	ADC	Pleural effusion	EGFR L858R	1	Osimeertinib	CK7(+);TTF1(+);NapsinA(+)
P-36	P-36-O1E	M	72	1	IVB	ADC	Pleural effusion	EGFR 20 ins	6	EMB-01	NA
P-37	P-37-O1T	F	67	1	IVB	ADC	Supraclavicular lymph node	NA	1	NA	NA
P-38	P-38-O1T	M	52	1	IVB	ADC	Supraclavicular lymph node	EGFR L858R	2	Osimeertinib+radiotherapy	NA
P-40	P-40-O1E	M	71	2	IVB	ADC	Pleural effusion	Negative	1	PCK	NA
P-41	P-41-O1E	F	59	1	IVA	ADC	Pleural effusion	EGFR 19 del;T790M	2	Osimeertinib	CK7(-);TTF1(-);NapsinA(+/-)
P-42	P-42-O1T	M	33	1	IVB	ADC	Supraclavicular lymph node	EGFR-RAD51 fusion	4	PCB	NA
P-43	P-43-O1E	F	49	1	IVA	ADC	Pleural effusion	EGFR 19 del;T790M	2	AZD9291 generic drug	CK7(+);TTF1(+);NapsinA(+)
P-44	P-44-O1E	F	52	1	IVA	ADC	Pleural effusion	EGFR 19 del;T790M	2	PCB	NA
P-45	P-45-O1E	M	69	1	IVB	ADC	Pleural effusion	EGFR L858R	3	Afatinib+Crizotinib	NA
P-46	P-46-O2T	M	68	1	IVA	ADC	Supraclavicular lymph node	KRAS p.G12C mutation	1	PCK	CK7(-);TTF1(-);NapsinA(+/-)
P-48	P-48-O1E	M	58	1	IVB	ADC	Pleural effusion	EGFR L858R	2	Erlotinib + Bevacizumab	CK7(+);TTF1(+);NapsinA(+)
P-49	P-49-O1E	M	70	3	IVB	ADC	Pleural effusion	Negative	3	Loratini	NA
P-49	P-49-O2E	M	70	3	IVB	ADC	Pleural effusion	Negative	3	Loratini	NA
P-49	P-49-O3E	M	70	3	IVB	ADC	Pleural effusion	Negative	3	Loratini	CK7(+);TTF1(-);NapsinA(-)
P-50	P-50-O1E	M	69	1	IVA	SCLC	Pleural effusion	NA	1	EP	CD56(-);CgA(-);Syn(-);TTF1(-)
P-51	P-51-O1E	M	63	1	IVB	SCC	Pleural effusion	Negative	1	Nab-paclitaxel + carboplatin	CK5/6(-);P63(+);P40(+)
P-51	P-51-O2E	M	63	1	IVB	SCC	Pleural effusion	Negative	1	Nab-paclitaxel + carboplatin	CK5/6(-)
P-51	P-51-O3E	M	63	1	IVB	SCC	Pleural effusion	Negative	1	Nab-paclitaxel + carboplatin	P63+

P-51	P-51-O4E	M	63	2	IVB	SCC	Pleural effusion	Negative	2	Best Supportive Care	CK5/6(-);P63(+);P40(+)
P-51	P-51-O5E	M	63	2	IVB	SCC	Pleural effusion	Negative	2	Best Supportive Care	CK5/6(+);P63(+);P40(+)
P-53	P-53-O1E	M	51	1	IVA	ADC	Pleural effusion	Negative	1	Pembrolizumab	NapsinA(-);TTF1(-);CK7(-)
P-54	P-54-O1E	F	40	1	IVB	ASC	Pleural effusion	NA	2	SAF-189s	NA
P-54	P-54-O2E	F	40	1	IVB	ASC	Pleural effusion	NA	2	SAF-189s	NA
P-54	P-54-O3E	F	40	1	IVB	ASC	Pleural effusion	NA	2	SAF-189s	NA
P-54	P-54-O4E	F	40	1	IVB	ASC	Pleural effusion	NA	2	SAF-189s	NA
P-54	P-54-O5E	F	40	1	IVB	ASC	Pleural effusion	NA	2	SAF-189s	NA
P-54	P-54-O6E	F	41	1	IVB	ASC	Pleural effusion	NA	2	SAF-189s	NA
P-54	P-54-O7E	F	41	1	IVB	ASC	Pleural effusion	NA	2	NA	NA
P-54	P-54-O8E	F	41	1	IVB	ASC	Pleural effusion	NA	2	NA	NA
P-54	P-54-O9E	F	41	1	IVB	ASC	Pleural effusion	NA	2	NA	NA
P-55	P-55-O1T	F	30	1	IVB	ADC	Lymph node	EGFR 19 del	5	Osimertinib	NA
P-56	P-56-O1E	M	55	1	IVA	ADC	Pleural effusion	ERBB2 20ins	1	PCB	NapsinA(-);TTF1(-);CK7(-)
P-56	P-56-O2E	M	55	1	IVA	ADC	Pleural effusion	ERBB2 20ins	1	PCB	NA
P-57	P-57-O1T	F	67	1	IVB	ADC	Chest wall tumor	NA	3	PCB	NapsinA(+);TTF1(-);CK7(+)
P-58	P-58-O1E	F	40	1	IVB	ADC	Pleural effusion	EGFR 20 ins	2	JNJ-61186372	NapsinA(-);TTF1(+);CK7(+)
P-58	P-58-O2E	F	40	1	IVB	ADC	Pleural effusion	EGFR 20 ins	2	JNJ-61186372	NA
P-59	P-59-O1E	F	50	3	IVB	ADC	Ascitic effusion	EGFR L858R;T790M	4	Osimertinib	NA
P-59	P-59-O2E	F	50	3	IVB	ADC	Ascitic effusion	EGFR L858R;T790M	4	Osimertinib	NapsinA(+);TTF1(+);CK7(+)
P-59	P-59-O3E	F	50	3	IVB	ADC	Ascitic effusion	EGFR L858R;T790M	4	Osimertinib	NapsinA(+);TTF1(+);CK7(+)
P-59	P-59-O4E	F	50	3	IVB	ADC	Ascitic effusion	EGFR L858R;T790M	4	Osimertinib	NapsinA(+);TTF1(+);CK7(+)
P-59	P-59-O5E	F	50	3	IVB	ADC	Pleural effusion	EGFR L858R;T790M	4	Osimertinib	NapsinA(-);TTF1(+);CK7(+)
P-60	P-60-O1T	M	55	1	IVB	ADC	Lymph node	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	NapsinA(+);TTF1(+);CK7(+)
P-60	P-60-O2E	M	55	1	IVB	ADC	Pericardial effusion	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	NapsinA(+);TTF1(-);CK7(+)
P-60	P-60-O3E	M	55	1	IVB	ADC	Pericardial effusion	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	NapsinA(+);TTF1(+);CK7(+)
P-60	P-60-O4E	M	55	1	IVB	ADC	Pericardial effusion	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	NapsinA(+);TTF1(-);CK7(+)
P-60	P-60-O5E	M	56	2	IVB	ADC	Pericardial effusion	EGFR L858R;MET amplification	4	Osimertinib + Savolitinib	NapsinA(+);TTF1(+);CK7(+)
P-61	P-61-O1E	F	51	3	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib +Cabozantinib	NapsinA(+);TTF1(+);CK7(+)
P-61	P-61-O2E	F	51	3	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib +Cabozantinib	NapsinA(+);TTF1(+);CK7(+)
P-61	P-61-O3E	F	51	3	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib +Cabozantinib	NapsinA(+);TTF1(+);CK7(+)
P-61	P-61-O4E	F	51	3	IVB	ADC	Pleural effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib +Cabozantinib	NapsinA(+);TTF1(+);CK7(+)
P-61	P-61-O5E	F	51	3	IVB	ADC	Pleural effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib +Cabozantinib	NapsinA(+);TTF1(+);CK7(+)
P-63	P-63-O1E	F	38	1	IVB	ADC	Pleural effusion	EML4-ALK fusion, ALK F1174C mutation	3	Alectinib	NA
P-63	P-63-O2E	F	38	1	IVB	ADC	Pleural effusion	EML4-ALK fusion, ALK F1174C mutation	3	Alectinib	NapsinA(+);TTF1(+);CK7(+)
P-63	P-63-O3E	F	38	1	IVB	ADC	Pleural effusion	EML4-ALK fusion, ALK F1174C mutation	3	Alectinib	NapsinA(+);CK7(+)
P-65	P-65-O1E	M	66	1	IIIC	SCLC	Pleural effusion	NA	1	EP	NA
P-69	P-69-O1E	M	65	3	IVA	ADC	Pericardial effusion	NA	1	Best Supportive Care	NA
P-69	P-69-O2E	M	65	3	IVA	ADC	Pericardial effusion	NA	1	Best Supportive Care	NA
P-69	P-69-O3E	M	65	3	IVA	ADC	Pleural effusion	Negative	1	Best Supportive Care	NapsinA(+);TTF1(+);CK7(+)
P-69	P-69-O4E	M	65	3	IVA	ADC	Pleural effusion	Negative	1	Best Supportive Care	NapsinA(+);TTF1(+);CK7(+)
P-69	P-69-O5E	M	65	3	IVA	ADC	Pleural effusion	Negative	1	Best Supportive Care	NapsinA(+);TTF1(+);CK7(+)
P-70	P-70-O1E	M	54	3	IVB	ADC	Pleural effusion	EGFR L858R	2	Osimertinib	NapsinA(-/+);TTF1(+);CK7(+)
P-70	P-70-O2E	M	54	3	IVB	ADC	Pleural effusion	EGFR L858R	2	Osimertinib	CK7(-);NapsinA(-);TTF1(-)
P-73	P-73-O1T	M	70	2	IVB	SCLC	Lymph node	NA	1	Nab-paclitaxel	CD56(+);CgA(+);Syn(+);TTF1(+)
P-74	P-74-O1T	F	68	1	IVB	ADC	Lymph node	EML4-ALK fusion	1	SAF-189s	NA
P-75	P-75-O1E	M	58	1	IVB	ADC	Pleural effusion	ERBB2 20ins	1	Pyrotinib	NapsinA(+);TTF1(+);CK7(+)
P-75	P-75-O2E	M	58	1	IVB	ADC	Pleural effusion	ERBB2 20ins	1	Pyrotinib	NapsinA(+);TTF1(+);CK7(+)
P-75	P-75-O3E	M	58	1	IVB	ADC	Pleural effusion	ERBB2 20ins	1	Pyrotinib	NapsinA(-);TTF1(+);CK7(+)
P-76	P-76-O1E	M	70	3	IVB	ADC	Pleural effusion	Negative	1	Pemetrexed + pembrolizumab	NapsinA(-);TTF1(+);CK7(+)
P-76	P-76-O2E	M	70	3	IVB	ADC	Pleural effusion	Negative	1	Pemetrexed + pembrolizumab	NapsinA(-);TTF1(-);CK7(+)
P-76	P-76-O3E	M	70	3	IVB	ADC	Pleural effusion	Negative	1	Pemetrexed + pembrolizumab	NA
P-77	P-77-O1E	F	70	1	IVA	ADC	Pleural effusion	EGFR L858R;T790M	2	Osimertinib	NapsinA(+);TTF1(+);CK7(+)
P-77	P-77-O2E	F	70	1	IVA	ADC	Pleural effusion	EGFR L858R;T790M	2	Osimertinib	NapsinA(+);TTF1(+);CK7(+)
P-78	P-78-O1E	F	50	1	IVB	ADC	Pleural effusion	EGFR L858R	1	Osimertinib	NapsinA(+);TTF1(-);CK7(+)
P-78	P-78-O2E	F	50	1	IVB	ADC	Pleural effusion	EGFR L858R	1	Osimertinib	NA
P-79	P-79-O1E	F	64	1	IVB	ADC	Ascitic effusion	EGFR L858R;T790M ;cis-C797S mutation	3	PCB	NapsinA(+);TTF1(+);CK7(+)

P-79	P-79-O2E	F	64	1	IVB	ADC	Ascitic effusion	EGFR L858R;T790M ;cis-C797S mutation	3	PCB	NapsinA(+);TTF1(+);CK7(+)
P-79	P-79-O3E	F	64	1	IVB	ADC	Ascitic effusion	EGFR L858R;T790M ;cis-C797S mutation	3	PCB	NapsinA(+);TTF1(+);CK7(+)
P-81	P-81-O1E	F	62	2	IVB	ADC	Pleural effusion	EGFR 19del	3	Nab-paclitaxel	NapsinA(-);TTF1(+);CK7(+); CD56(-);CgA(-);Syn(+)
P-82	P-82-O1E	M	75	2	IVA	SCLC	Pleural effusion	NA	1	Nab-paclitaxel	CD56(-);CgA(-);Syn(+)
P-83	P-83-O1E	M	77	1	IVB	SCLC	Pleural effusion	NA	1	EC	CD56(-);CgA(+);Syn(+);TTF1(+)
P-84	P-84-O1E	M	54	1	IVB	SCLC	Pleural effusion	NA	1	NA	NA
P-85	P-85-O1E	F	32	1	IVB	ADC	Ascitic effusion	EGFR 19 del	4	TDM1	NapsinA(+);TTF1(+);CK7(+)
P-85	P-85-O2E	F	32	1	IVB	ADC	Ascitic effusion	EGFR 19 del	4	TDM1	NapsinA(+);TTF1(+);CK7(+)
P-85	P-85-O3E	F	32	1	IVB	ADC	Ascitic effusion	EGFR 19 del	4	Nab-paclitaxel +anlotinib	NapsinA(+);TTF1(+);CK7(+)
P-86	P-86-O1E	F	74	1	IVA	ADC	Pleural effusion	MET 14 skipping	1	Bozitinib	CK7(+)
P-87	P-87-O1E	F	51	1	IVA	ASC	Pleural effusion	EGFR L858R	1	Afatinib	CK5/6(-);P63(-);P40(-); NapsinA(-);TTF1(+);CK7(+)
P-87	P-87-O2E	F	51	1	IVA	ASC	Pleural effusion	EGFR L858R	1	Afatinib	CK5/6(-);P63(-);P40(-); NapsinA(-);TTF1(-);CK7(+)
P-87	P-87-O3E	F	51	1	IVA	ASC	Pleural effusion	EGFR L858R	1	Afatinib	CK5/6(-);P63(-);P40(-); NapsinA(-);TTF1(-);CK7(+)
P-88	P-88-O1E	F	82	1	IVA	ADC	Pleural effusion	NA	1	NA	NapsinA(+);TTF1(+);CK7(+)
P-89	P-89-O1E	M	28	1	IVB	ADC	Pleural effusion	EGFR 19 del	1	Osimertinib	NapsinA(+);TTF1(-);CK7(+)
P-89	P-89-O2E	M	28	1	IVB	ADC	Pleural effusion	EGFR 19 del	1	Osimertinib	NapsinA(+);TTF1(-);CK7(+)
P-90	P-90-O1E	F	58	4	IVB	SCC	Pleural effusion	EGFR 19 del	2	Osimertinib	NA
P-90	P-90-O2E	F	58	4	IVB	SCC	Pleural effusion	EGFR 19 del	2	Osimertinib	NA
P-93	P-93-O1E	M	55	1	IVA	ADC	Pleural effusion	EML4-ALK fusion	3	Nab-paclitaxel+Carboplatin + Be	NapsinA(+);TTF1(+);CK7(+)
P-94	P-94-O1E	M	58	1	IVB	ADC	Pleural effusion	NA	2	Afatinib+IP	NA
P-94	P-94-O2E	M	58	1	IVB	ADC	Pleural effusion	NA	2	Afatinib+IP	NapsinA(-);TTF1(-)
P-94	P-94-O3E	M	58	1	IVB	ADC	Pleural effusion	NA	2	Afatinib+IP	NapsinA(-);TTF1(-);CK7(+)
P-95	P-95-O1E	F	62	1	IVB	ADC	Pleural effusion	BRAF V600E	1	Darafenib + trametinib	NapsinA(+);TTF1(+);CK7(+)
P-95	P-95-O2E	F	62	1	IVB	ADC	Pleural effusion	BRAF V600E	1	Darafenib + trametinib	NA
P-95	P-95-O3E	F	62	1	IVB	ADC	Pleural effusion	BRAF V600E	1	Darafenib + trametinib	NapsinA(+);TTF1(+);CK7(+)
P-96	P-96-O1E	F	75	4	IVA	ADC	Pleural effusion	EGFR 19 del	3	NA	NapsinA(-);TTF1(-);CK7(-)
P-96	P-96-O2E	F	75	4	IVA	ADC	Pleural effusion	EGFR 19 del	3	NA	NapsinA(-);TTF1(-);CK7(-)
P-96	P-96-O3E	F	75	4	IVA	ADC	Pleural effusion	EGFR 19 del	3	NA	NapsinA(-);TTF1(-);CK7(-)
P-97	P-97-O1E	M	59	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M	2	PLB1004	NapsinA(+);TTF1(+);CK7(+)
P-97	P-97-O2E	M	59	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M	2	PLB1004	NapsinA(+);TTF1(+);CK7(+)
P-97	P-97-O3E	M	59	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M	2	PLB1004	NapsinA(+);TTF1(+);CK7(+)
P-98	P-98-O1E	M	54	1	IVB	ADC	Pleural effusion	EGFR 19 del	1	Afatinib	NA
P-98	P-98-O2E	M	54	1	IVB	ADC	Pleural effusion	EGFR 19 del	1	Afatinib	NA
P-98	P-98-O3E	M	54	1	IVB	ADC	Pleural effusion	EGFR 19 del	1	Afatinib	NA
P-99	P-99-O1E	M	72	1	IVA	SCLC	Pleural effusion	NA	1	EC	NA
P-99	P-99-O2E	M	72	1	IVA	SCLC	Pleural effusion	NA	1	EC	NA
P-100	P-100-O1E	M	35	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M ;cis-C797S mutation	3	TQB3804	NapsinA(+);TTF1(+);CK7(+)
P-100	P-100-O2E	M	35	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M ;cis-C797S mutation	3	TQB3804	NA
P-100	P-100-O3E	M	35	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M ;cis-C797S mutation	3	TQB3804	TTF1(-);CK7(-)
P-101	P-101-O1E	M	66	2	IVB	ADC	Pericardial effusion	EGFR 20 ins	1	NA	NapsinA(+);TTF1(+);CK7(+)
P-101	P-101-O2E	M	66	2	IVB	ADC	Pericardial effusion	EGFR 20 ins	1	NA	NapsinA(+);TTF1(+);CK7(+)
P-101	P-101-O3E	M	66	2	IVB	ADC	Pericardial effusion	EGFR 20 ins	1	NA	NapsinA(-);TTF1(-);CK7(+)
P-102	P-102-O1E	F	52	1	IVB	SCC	Pleural effusion	KIF5B-RET fusion	2	LOXO-292	NA
P-102	P-102-O2E	F	52	1	IVB	SCC	Pleural effusion	KIF5B-RET fusion	2	LOXO-292	NA
P-103	P-103-O1E	M	39	1	IVA	ADC	Pericardial effusion	EML4-ALK fusion	3	NA	NA
P-103	P-103-O2E	M	39	1	IVA	ADC	Pleural effusion	EML4-ALK fusion	3	NA	NA
P-103	P-103-O3E	M	39	1	IVA	ADC	Pleural effusion	EML4-ALK fusion	3	Nab-paclitaxel+Carboplatin + Be	NA
P-103	P-103-O4E	M	39	1	IVA	ADC	Pleural effusion	EML4-ALK fusion	3	Nab-paclitaxel+Carboplatin + Be	NA
P-105	P-105-O1T	M	59	1	IVB	SAR	Muscle mass	MET 14 skipping	1	Crizotinib	NA
P-106	P-106-O1T	M	60	1	IIIB	SCC	Lung tissue	NA	1	NA	CK5/6(++);P63(+);P40(+)
P-107	P-107-O1E	F	48	1	IVB	SCLC	Pleural effusion	NA	4	ABCP	CgA(+);Syn(+);CD56(+)

Abbreviations:IHC: immunohistochemistry; M: male; F: female; SCLC: small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; ASC: adenosquamous carcinoma; SAR: sarcomatoid carcinoma; NA: not available;

IC50: half-maximal inhibitory concentration; EP: Etoposide + Cisplatin; IP: Irinotecan + Carboplatin; PCB: Pemetrexed + Carboplatin + Bevacizumab; ABCP: Atezolizumab + + Bevacizumab + Carboplatin + Paclitaxel; PC:

Pemetrexed + Carboplatin; PCK: Pemetrexed + carboplatin + pembrolizumab; EC: Etoposide + Carboplatin; Driver mutation: EGFR, ALK, HER2, MET, RET, ROS1, BRAF, KRAS.

Table S2. The list of lung cancer samples used for failed establishment of patient-derived organoids. Related to Figure 1A.

Case	Organoid ID	Culture Results	Cell counts	Gender	Age	ECOG		Treatment lines	Pathology	Site of sampling	Driver mutation detected by routine genetic testing or FISH
						PS score	Stage				
P-3	P-3-F1T	Failure	2.32×10 ³	M	50	1	IVB	4	SCLC	Paravertebral tumor	NA
P-4	P-4-F1T	Failure	N/A	M	65	1	IVB	3	ADC	Supraclavicular lymph node	EGFR 19del
P-5	P-5-F1T	Failure	N/A	M	61	3	IVB	5	ADC	Chest wall tumor	NA
P-6	P-6-F1T	Failure	N/A	F	57	0	IVB	7	SCLC	Abdominal neoplasm	EGFR 19del
P-8	P-8-F1E	Failure	N/A	F	80	1	IVB	3	ADC	Pleural effusion	NA
P-15	P-15-F1E	Failure	N/A	F	64	3	IVB	4	NO Tumor cells	Pleural effusion	NA
P-17	P-17-F1E	Failure	2.50×10 ⁶	F	41	1	IVB	3	ADC	Pleural effusion	EGFR 19del
P-17	P-17-F2T	Failure	4.02×10 ⁶	F	41	1	IVB	3	ADC	Brain metastases	EGFR 19del
P-19	P-19-F1T	Failure	N/A	F	68	2	IVB	2	ADC	Thoracic tumor	EGFR L858R
P-20	P-20-F1E	Failure	N/A	F	62	4	IVB	5	ADC	Pleural effusion	NA
P-21	P-21-F1T	Failure	N/A	M	65	1	IVB	3	ADC	Liver tissue	MET 14 skipping
P-22	P-22-F1T	Failure	N/A	M	38	2	IVB	2	SCLC	Scapular mass	EGFR L858R
P-25	P-25-F1E	Failure	N/A	F	32	1	IVB	4	NA	Cerebrospinal fluid	CD74-ROS1 fusion
P-26	P-26-F1T	Failure	N/A	M	39	2	IVB	4	ADC	Axillary lymph node	EGFR 19del
P-27	P-27-F1T	Failure	4.50×10 ⁵	M	55	3	IVB	2	ADC	Chest wall tumor	EML4-ALK fusion
P-29	P-29-F1T	Failure	N/A	F	59	1	IVB	5	ADC	Liver tissue	NA
P-31	P-31-F1T	Failure	N/A	F	48	2	IVB	5	ADC	Liver tissue	EGFR L858R,T790M
P-35	P-35-F1T	Failure	2.20×10 ⁵	M	57	2	IVB	4	ADC	Liver tissue	NA
P-36	P-36-F1E	Failure	N/A	M	72	1	IVB	9	ADC	Pleural effusion	EGFR 20 ins
P-39	P-39-F1T	Failure	3.20×10 ⁵	M	44	1	IVB	1	ADC	Supraclavicular lymph node	EGFR 19del
P-40	P-40-F1E	Failure	2.43×10 ²	M	71	1	IVB	1	NO Tumor cells	Pleural effusion	Negative
P-47	P-47-F1T	Failure	2.85×10 ⁵	M	60	1	IVB	1	SCC	Supraclavicular lymph node	Negative
P-51	P-51-F1E	Failure	9.80×10 ⁵	M	64	2	IVB	2	SCC	Pleural effusion	Negative
P-52	P-52-F1E	Failure	1.19×10 ⁷	M	72	1	IVB	2	SCLC	Pleural effusion	NA
P-52	P-52-F2E	Failure	3.27×10 ⁵	M	72	1	IVB	2	SCLC	Pleural effusion	NA
P-52	P-52-F3E	Failure	2.00×10 ³	M	72	1	IVB	2	SCLC	Pleural effusion	NA
P-56	P-56-F1E	Failure	2.60×10 ⁵	M	55	1	IVB	2	ADC	Pleural effusion	ERBB2 20ins
P-59	P-59-F1E	Failure	7.22×10 ⁶	F	50	3	IVB	3	ADC	Abdominal cavity effusion	EGFR L858R,T790M
P-62	P-62-F1T	Failure	1.50×10 ³	M	54	1	IVA	4	ADC	Lymph node	EGFR L858R
P-64	P-64-F1T	Failure	3.50×10 ²	F	73	1	IVB	2	NO Tumor cells	Lymph node	NA
P-66	P-66-F1E	Failure	2.52×10 ⁶	F	54	1	IVB	2	ADC	Pleural effusion	EGFR 19del ,T790M
P-67	P-67-F1E	Failure	6.04×10 ³	M	74	1	IVA	1	NO Tumor cells	Pleural effusion	NA
P-67	P-67-F2E	Failure	1.56×10 ⁶	M	74	1	IVA	1	NO Tumor cells	Pleural effusion	NA
P-67	P-67-F3E	Failure	1.51×10 ⁶	M	74	1	IVA	1	NO Tumor cells	Pleural effusion	NA
P-68	P-67-F4T	Failure	0	M	51	1	IVA	2	ADC	Lymph node	EGFR 19del
P-71	P-71-F1T	Failure	1.44×10 ⁶	F	55	1	IVA	1	ADC	Lymph node	RET fusion
P-72	P-72-F1T	Failure	2.65×10 ³	M	65	1	IVA	1	SCC	Lymph node	Negative
P-78	P-78-F1E	Failure	1.74×10 ⁷	F	50	1	IVB	1	ADC	Pleural effusion	EGFR L858R
P-80	P-80-F1T	Failure	1.50×10 ²	F	46	1	IVB	1	ADC	Lymph node	EGFR L858R
P-81	P-81-F1E	Failure	3.27×10 ⁶	F	62	2	IVB	3	SCLC	Pleural effusion	EGFR 19del

P-82	P-82-F1E	Failure	6.45×10 ⁵	M	75	2	IVB	1	SCLC	Pleural effusion	NA
P-82	P-82-F2E	Failure	9.00×10 ³	M	75	2	IVB	1	NO Tumor cells	Pleural effusion	NA
P-89	P-89-F1T	Failure	2.50×10 ²	M	28	1	IVB	1	ADC	Supraclavicular lymph node	EGFR 19del
P-90	P-90-F1E	Failure	3.00×10 ³	F	58	4	IVB	2	SCC	Pleural effusion	Negative
P-91	P-91-F1E	Failure	1.33×10 ³	M	57	1	IIIB	2	NO Tumor cells	Pleural effusion	NA
P-91	P-91-F2E	Failure	3.10×10 ³	M	57	1	IIIB	2	NO Tumor cells	Pleural effusion	NA
P-91	P-91-F3E	Failure	4.00×10 ³	M	57	1	IIIB	2	NO Tumor cells	Pleural effusion	NA
P-92	P-92-F1E	Failure	3.40×10 ³	F	56	1	IVB	1	ASC	Pleural effusion	NA
P-102	P-102-F1E	Failure	4.30×10 ²	F	52	1	IVB	2	SCC	Pleural effusion	KIF5B-RET fusion
P-103	P-103-F1E	Failure	1.75×10 ³	M	39	1	IVB	3	ADC	Pericardial effusion	EML4-ALK fusion
P-103	P-103-F2E	Failure	1.54×10 ³	M	39	1	IVB	3	ADC	Pericardial effusion	EML4-ALK fusion
P-104	P-104-F1E	Failure	2.00×10 ³	M	62	2	IVB	2	ADC	Cerebrospinal fluid	EGFR 19 del

Abbreviations: IHC: immunohistochemistry; M: male; F: female; SCLC: small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; NA: not available; N/A: The cell counter cannot count due to insufficient number of cells; Driver mutation: EGFR, ALK, HER2, MET, RET, ROS1, BRAF, KRAS.

Table S3. Univariate model and multivariate model for organoid culture. Related to Figure 1A.

Factors	Cases	Univariate model			Multivariate model		
		Odds Ratio	95% CI	<i>P</i>	Odds	95% CI	<i>P</i>
Gender							
Male	117	Reference					
Female	97	0.55	(0.25 - 1.17)	0.1213			
Age							
<65	155	Reference					
≥65	59	1.63	(0.69 - 3.87)	0.2662			
ECOG PS							
0-1	145	Reference					
≥2	69	0.96	(0.43 - 2.14)	0.9195			
Stage							
IIIB-IVA	49	Reference					
IVB	165	1.41	(0.55 - 3.64)	0.4805			
Pathology							
ADC	156	6			Reference		
Other	58	0.13	(0.05 - 0.32)	<0.0001	0.21	(0.10 - 0.43)	<0.0001
Lines of treatment							
1	69	Reference					
≥2	145	2.30	(0.92 - 5.72)	0.0736			
Sampling type							
Tissue	162	Reference			Reference		
Effusion	52	4.47	(2.01 - 9.91)	0.0002	4.50	(2.12 - 9.53)	<0.0001
Gene							
<i>EGFR</i>	76	Reference					
Other	52	0.68	(0.25 - 1.90)	0.4657			
Negative	23	0.53	(0.13 - 2.20)	0.3815			
NA	63	0.46	(0.17 - 1.24)	0.1247			

Abbreviations: ADC: adenocarcinoma; NA: not available; *EGFR*: epidermal growth factor receptor

Table S4. The clinicopathological characteristics of genomic profiling cohort. Related to Figure 2A.

Characteristics	No. (%)
Age (median[range], years)	55[32-75]
Gender	
Female	12 (48%)
Male	13 (52%)
Histology	
ADC	22 (88%)
SCC	2 (8%)
ASC	1 (4%)
Stage	
IVA	8 (32%)
IVB	17 (68%)
Treatment line	
1	8 (32%)
2	7 (28%)
3	7 (28%)
4	2 (8%)
6	1 (4%)
Total	25

Abbreviations: SCLC: small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma.

Table S5. List of genes for paired-samples. Related to Figure 2A.

Case	Organoid	Gene	Description	Mutation Type	Match.status
P-25	P-25-O1E	ROS1	CD74-ROS1	gene fusion	Match
P-25	P-25-O1E	ROS1	p.G2032R	missense variant	Match
P-25	P-25-O1E	ROS1	ROS1-intergenic(VIP,FBXO5)	gene fusion	Match
P-48	P-48-O1E	DNAJB1	p.R249T	missense variant	LCO only
P-48	P-48-O1E	EGFR	p.L858R	missense variant	Match
P-48	P-48-O1E	MAP2K4	p.D296H	missense variant	LCO only
P-48	P-48-O1E	PIK3R1	c.1745+1G>A	splice donor variant	LCO only
P-51	P-51-O1E	DNMT3A	p.N776T	missense variant	Match
P-51	P-51-O1E	FLT1	p.F192L	missense variant	Match
P-51	P-51-O1E	IL7R	cn amp	cn amp	Match
P-51	P-51-O1E	KMT2D	p.T4602fs	frameshift variant	Match
P-51	P-51-O1E	LRP1B	p.R3072I	missense variant	Match
P-51	P-51-O1E	MYC	cn amp	cn amp	LCO only
P-51	P-51-O1E	NFE2L2	p.R34Q	missense variant	Match
P-51	P-51-O1E	PIK3CA	p.E542K	missense variant	Match
P-51	P-51-O1E	PIK3CA	p.E545Q	missense variant	Match
P-51	P-51-O1E	PTEN	p.C211=	splice region variant	Match
P-51	P-51-O1E	RICTOR	cn amp	cn amp	Match
P-51	P-51-O1E	SPTA1	p.E813K	missense variant	Match
P-51	P-51-O1E	TET2	c.3410-1G>C	splice acceptor variant	Match
P-51	P-51-O1E	TP53	p.Q331H	splice region variant	Match
P-51	P-51-O1E	WT1	cn amp	cn amp	LCO only
P-51	P-51-O1E	XRCC2	p.A16S	missense variant	Match
P-51	P-51-O1E	ZBTB2	p.R189G	missense variant	Match
P-56	P-56-O1E	ERBB2	p.G778 P780dup	disruptive inframe insertion	Match
P-56	P-56-O1E	PIK3CG	p.E556G	missense variant	effusion only
P-56	P-56-O1E	RB1	exon18-23cn del	large genomic rearrangemen	effusion only
P-56	P-56-O1E	TP53	c.673-2A>T	splice acceptor variant	Match
P-59	P-59-O1E	EGFR	p.L858R	missense variant	Match
P-59	P-59-O1E	EGFR	p.T790M	missense variant	Match
P-59	P-59-O1E	TP53	p.Y234D	missense variant	Match
P-59	P-59-O1E	U2AF1	p.S19L	missense variant	Match
P-60	P-60-O4E	EGFR	p.L858R	missense variant	Match
P-60	P-60-O4E	FANCA	p.M569 E570delinsIG	missense variant	effusion only
P-60	P-60-O4E	SLX4	c.5153+1G>A	splice donor variant	effusion only
P-60	P-60-O4E	TP53	p.S215R	missense variant	Match
P-61	P-61-O5E	EGFR	p.E746 A750del	conservative inframe deletio	Match
P-61	P-61-O5E	EGFR	p.T790M	missense variant	Match
P-61	P-61-O5E	KRAS	cn del	cn del	effusion only
P-61	P-61-O5E	RET	CCDC6-RET	gene fusion	Match
P-61	P-61-O5E	SMAD4	cn del	cn del	effusion only
P-61	P-61-O5E	SMAD4	p.D537H	missense variant	Match
P-61	P-61-O5E	TP53	p.R282W	missense variant	Match
P-77	P-77-O1E	ALK	p.Q897L	missense variant	LCO only
P-77	P-77-O1E	ALK	p.T901A	missense variant	LCO only
P-77	P-77-O1E	ARID1A	p.A226P	missense variant	LCO only
P-77	P-77-O1E	ARID1A	p.G1351S	missense variant	LCO only
P-77	P-77-O1E	ARID1A	p.S949P	missense variant	LCO only
P-77	P-77-O1E	CARD11	cn amp	cn amp	effusion only
P-77	P-77-O1E	CTNNB1	p.S37C	missense variant	effusion only
P-77	P-77-O1E	DNMT3A	c.2322+7_2322+12delinsACC GAG	splice_region_variant	LCO only
P-77	P-77-O1E	EGFR	cn amp	cn amp	effusion only
P-77	P-77-O1E	EGFR	p.L858R	missense variant	Match
P-77	P-77-O1E	EGFR	p.T790M	missense variant	Match
P-77	P-77-O1E	ERCC2	p.R26L	missense variant	LCO only
P-77	P-77-O1E	EWSR1	p.M330L	missense variant	LCO only
P-77	P-77-O1E	FLT4	p.G513E	missense variant	Match
P-77	P-77-O1E	GID4	p.A98 A99delinsTT	missense variant	LCO only

P-77	P-77-O1E	IKZF1	cn amp	cn amp	effusion only
P-77	P-77-O1E	KDR	p.C1045*	stop gained	Match
P-77	P-77-O1E	KMT2A	p.N3494D	missense variant	effusion only
P-77	P-77-O1E	KMT2D	c.13840-17_13840-4delinsACCCCACCCCC	splice_region_variant	LCO only
P-77	P-77-O1E	LRP1B	p.D1946V	missense variant	effusion only
P-77	P-77-O1E	MED12	p.P1946S	missense variant	LCO only
P-77	P-77-O1E	MED12	p.S63N	missense variant	LCO only
P-77	P-77-O1E	PPP2R1A	p.E393Q	missense variant	Match
P-77	P-77-O1E	PPP2R2A	exon2del	large genomic rearrangement	LCO only
P-77	P-77-O1E	PPP2R2A	exon4-5del	large genomic rearrangement	LCO only
P-77	P-77-O1E	RB1	c.1128-1G>A	splice acceptor variant	Match
P-77	P-77-O1E	RBM10	exon6del	large genomic rearrangement	LCO only
P-77	P-77-O1E	RUNX1	p.A63G	missense variant	LCO only
P-77	P-77-O1E	SOX17	p.L148M	missense variant	LCO only
P-77	P-77-O1E	TMPRSS2	p.N314G	missense variant	LCO only
P-77	P-77-O1E	TP53	p.E198*	stop gained	Match
P-77	P-77-O1E	VEGFA	p.H161R	missense variant	LCO only
P-77	P-77-O1E	ZNF703	p.S20delinsGGSSSG	conservative_inframe_insertion	LCO only
P-78	P-78-O1E	EGFR	p.L858R	missense variant	Match
P-78	P-78-O1E	NKX2-1	cn amp	cn amp	Match
P-78	P-78-O1E	TP53	p.S241Y	missense variant	Match
P-28	P-28-O1E	ARID1A	p.P1018L	missense variant	effusion only
P-28	P-28-O1E	MSH6	p.E1324K	missense variant	effusion only
P-28	P-28-O1E	ROS1	CD74-ROS1	gene fusion	Match
P-87	P-87-O2E	EGFR	p.L858R	missense variant	Match
P-87	P-87-O2E	IL7R	cn amp	cn amp	effusion only
P-87	P-87-O2E	KMT2D	p.A230T	missense variant	Match
P-87	P-87-O2E	PTEN	exon3-5del	large genomic rearrangement	effusion only
P-87	P-87-O2E	RB1	CD59-RB1	gene fusion	Match
P-87	P-87-O2E	RB1	RB1-CD59	gene fusion	Match
P-87	P-87-O2E	RICTOR	cn amp	cn amp	effusion only
P-87	P-87-O2E	RPA1	SMG6-RPA1	gene fusion	effusion only
P-87	P-87-O2E	SDHA	cn amp	cn amp	effusion only
P-87	P-87-O2E	TERT	cn amp	cn amp	effusion only
P-87	P-87-O2E	TET1	p.K585N	missense variant	Match
P-87	P-87-O2E	TP53	p.R110L	missense variant	effusion only
P-96	P-96-O2E	EGFR	cn amp	cn amp	effusion only
P-96	P-96-O2E	EGFR	p.E746 A750del	conservative inframe deletion	Match
P-96	P-96-O2E	PTEN	p.G129R	missense variant	Match
P-96	P-96-O2E	RB1	p.I723fs	frameshift variant	Match
P-96	P-96-O2E	TP53	p.L194P	missense variant	Match
P-97	P-97-O1E	ASXL1	cn amp	cn amp	effusion only
P-97	P-97-O1E	CREBBP	p.A619T	missense variant	Match
P-97	P-97-O1E	EGFR	p.L858R	missense variant	Match
P-97	P-97-O1E	EGFR	p.T790M	missense variant	Match
P-97	P-97-O1E	HIST1H3	p.K28R	missense variant	Match
P-97	P-97-O1E	KRAS	cn amp	cn amp	effusion only
P-97	P-97-O1E	SRC	cn amp	cn amp	effusion only
P-97	P-97-O1E	TP53	p.N239S	missense variant	Match
P-30	P-30-O2E	EGFR	p.E746 A750del	inframe deletion	Match
P-30	P-30-O2E	EGFR	p.T790M	missense variant	Match
P-30	P-30-O2E	FGFR3	p.R112W	missense variant	effusion only
P-30	P-30-O2E	GATA4	p.V48M	missense variant	Match
P-30	P-30-O2E	MTOR	p.R1749*	stop gained	Match
P-30	P-30-O2E	RB1	cn del	cn del	effusion only
P-30	P-30-O2E	RET	RABEP2-RET	gene fusion	Match
P-30	P-30-O2E	TERT	p.A68T	missense variant	effusion only
P-30	P-30-O2E	TP53	p.A276G	missense variant	Match
P-30	P-30-O3E	EGFR	p.E746 A750del	inframe deletion	Match

P-30	P-30-O3E	EGFR	p.T790M	missense variant	Match
P-30	P-30-O3E	GATA4	p.V48M	missense variant	Match
P-30	P-30-O3E	MTOR	p.R1749*	stop gained	Match
P-30	P-30-O3E	NTRK1	FAM118A-NTRK1	gene fusion	Match
P-30	P-30-O3E	RET	RABEP2-RET	gene fusion	Match
P-30	P-30-O3E	TP53	p.A276G	missense variant	Match
P-36	P-36-O1E	EGFR	p.D770 N771insG	inframe insertion	Match
P-36	P-36-O1E	TP53	p.Y220D	missense variant	Match
P-41	P-41-O1E	ATRX	p.S1174C	missense variant	effusion only
P-41	P-41-O1E	BCL6	p.R668C	missense variant	effusion only
P-41	P-41-O1E	EGFR	cn amp	cn amp	Match
P-41	P-41-O1E	EGFR	p.E746 A750del	disruptive inframe deletion	Match
P-41	P-41-O1E	EGFR	p.T790M	missense variant	Match
P-41	P-41-O1E	FOXA1	cn amp	cn amp	effusion only
P-41	P-41-O1E	NFKBIA	cn amp	cn amp	effusion only
P-41	P-41-O1E	NKX2-1	cn amp	cn amp	effusion only
P-41	P-41-O1E	RICTOR	p.V165M	missense variant	effusion only
P-41	P-41-O1E	TP53	p.V157F	missense variant	Match
P-43	P-43-O1E	BRCA1	p.L1800fs	frameshift variant	Match
P-43	P-43-O1E	EGFR	p.E746 A750del	disruptive inframe deletion	Match
P-43	P-43-O1E	EGFR	p.T790M	missense variant	Match
P-43	P-43-O1E	FANCM	p.S14L	missense variant	Match
P-43	P-43-O1E	FOXA1	cn amp	cn amp	LCO only
P-43	P-43-O1E	NFKBIA	cn amp	cn amp	LCO only
P-43	P-43-O1E	NKX2-1	cn amp	cn amp	LCO only
P-43	P-43-O1E	PPM1D	PPM1D-SPECC1	gene fusion	effusion only
P-43	P-43-O1E	RB1	exon18-23del	large genomic rearrangemen	LCO only
P-43	P-43-O1E	TP53	p.R175H	missense variant	Match
P-44	P-44-O1E	CDK4	cn amp	cn amp	Match
P-44	P-44-O1E	CDK6	p.G157E	missense variant	Match
P-44	P-44-O1E	EGFR	cn amp	cn amp	Match
P-44	P-44-O1E	EGFR	p.E746 A750del	disruptive inframe deletion	Match
P-44	P-44-O1E	EGFR	p.T790M	missense variant	Match
P-44	P-44-O1E	MDM2	cn amp	cn amp	Match
P-44	P-44-O1E	RBM10	p.E112*	stop gained	Match
P-44	P-44-O1E	SPTA1	p.W173C	missense variant	effusion only
P-45	P-45-O1E	CCNE1	cn amp	cn amp	LCO only
P-45	P-45-O1E	CD274	cn amp	cn amp	LCO only
P-45	P-45-O1E	PDCD1L	cn amp	cn amp	LCO only
P-45	P-45-O1E	TERT	cn amp	cn amp	LCO only
P-45	P-45-O1E	TP53	p.V218E	missense variant	effusion only
P-45	P-45-O1E	TP53	TP53-IGR (downstream	large genomic rearrangemen	effusion only
P-45	P-45-O1E	TSC1	p.L72V	missense variant	LCO only
P-45	P-45-O1E	WRN	p.S1256*	stop gained	Match
P-45	P-45-O1E	NF1	p.D801H	missense variant	Match
P-45	P-45-O1E	FBXW7	p.S180C	missense variant	effusion only
P-45	P-45-O1E	EGFR	p.L858R	missense variant	Match
P-45	P-45-O1E	MYCN	p.K304E	missense variant	Match
P-45	P-45-O1E	EWSR1	p.D412N	missense variant	Match
P-45	P-45-O1E	FANCG	cn amp	cn amp	LCO only
P-45	P-45-O1E	INPP4B	cn amp	cn amp	LCO only
P-45	P-45-O1E	LYN	cn amp	cn amp	LCO only
P-45	P-45-O1E	MET	cn amp	cn amp	LCO only
P-45	P-45-O1E	NBN	cn amp	cn amp	LCO only
P-45	P-45-O1E	PAX5	cn amp	cn amp	LCO only
P-45	P-45-O1E	POLE	p.F699fs	frameshift variant	LCO only

Table S6. Clinical characteristics and drug susceptibility results in four groups. Related to Figure 3 and S3.

Case	Organoid ID	Gender	Age	ECOG PS score	Stage	Pathology	Site of sampling	Driver mutation detected by routine genetic testing or FISH	Treatment Lines	LCO-DST regimen used as next-line treatment in the patient	IC ₅₀ (μM)	Clinical Response	Consistency	Other LCO-DST regimen NOT used in the patient (regimen, IC ₅₀)
Osimertinib group														
P-17	P-17-O2E	F	41	1	IVB	ADC	Pleural effusion	EGFR 19 del	2	Osimertinib	1.77	PD	NO	PC, 22.95
P-18	P-18-O1T	M	80	3	IVB	ADC	Supraclavicular lymph node	EGFR L858R;T790M	2	Osimertinib	7.73	PD	YES	Larotrectinib, 1479 Alectinib, 10.18; Cabozantinib, 15.09;
P-30	P-30-O2E	M	50	2	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M; RET fusion	4	Osimertinib	3.46	PD	YES	Osimertinib + Cabozantinib, 0.75; Alectinib, 13.62; Cabozantinib, 48.85;
P-30	P-30-O3E	M	50	2	IVB	ADC	Pleural effusion	EGFR 19 del; T790M; FAM118A-NTRK1 fusion; RET fusion	4	Osimertinib	5.59	PD	YES	Osimertinib + Cabozantinib, 2.19; Osimertinib + CBL0137, 0.20;
P-32	P-32-O1T	F	69	1	IIIB	ADC	Lymph node	EGFR L858R;T790M	1	Osimertinib	0.12	PR	YES	Osimertinib + Cetuximab, 0.51; Osimertinib + PC. 1.21 Afatinib, 0.01;
P-34	P-34-O1E	M	41	2	IVB	ADC	Pleural effusion	EGFR L858R	1	Osimertinib	1.9	PR	YES	Osimertinib + CBL0137, 0.62; Osimertinib + Cetuximab. 2.52 Afatinib, 0.33;
P-41	P-41-O1E	F	59	1	IVA	ADC	Pleural effusion	EGFR 19 del;T790M	2	Osimertinib	0.1	PR	YES	Dacomitinib, 0.61; PLB1004, 1.41; PC 23.20
P-59	P-59-O1E	F	50	3	IVB	ADC	Ascitic effusion	EGFR L858R;T790M	4	Osimertinib	4.37	PD	YES	Gefitinib, 6.59
P-59	P-59-O5E	F	50	3	IVB	ADC	Pleural effusion	EGFR L858R;T790M	4	Osimertinib	15.5	PD	YES	Gefitinib, 16.69; Osimertinib + GDC-0941, 3.42
P-70	P-70-O1E	M	54	3	IVB	ADC	Pleural effusion	EGFR L858R	2	Osimertinib	2.68	PD	YES	Afatinib, 7.98
P-77	P-77-O2E	F	70	1	IVA	ADC	Pleural effusion	EGFR L858R;T790M	2	Osimertinib	2.14	PR	YES	Afatinib, 2.36
P-78	P-78-O2E	F	50	1	IVB	ADC	Pleural effusion	EGFR L858R	1	Osimertinib	1.23	PR	YES	NA
P-89	P-89-O2E	M	28	1	IVB	ADC	Pleural effusion	EGFR 19 del	1	Osimertinib	0.33	PR	YES	NA
P-90	P-90-O1E	F	58	4	IVB	SCC	Pleural effusion	EGFR 19 del	2	Osimertinib	1.96	PD	NO	Afatinib, 0.30
P-90	P-90-O2E	F	58	4	IVB	SCC	Pleural effusion	EGFR 19 del	2	Osimertinib	2.43	PD	YES	Afatinib, 0.04
Other targeted group														
P-27	P-27-O1E	M	55	3	IVB	ADC	Pericardial effusion	EML4-ALK fusion	3	Crizotinib	1.47	PD	YES	Lorlatinib, 12.38; Alectinib, 17.65; Crizotinib + Alectinib, 1.25; Crizotinib + Lorlatinib 1.59 Crizotinib, 4.30;
P-33	P-33-O1E	F	54	1	IVA	ADC	Pleural effusion	EML4-ALK fusion, ALK-C17orf75 fusion	1	Alectinib	0.59	PR	YES	Lorlatinib, 26.88; Alectinib + CBL0137. 0.59 Crizotinib, 1.32;
P-33	P-33-O2T	F	54	1	IVA	ADC	Supraclavicular lymph node	EML4-ALK fusion	1	Alectinib	0.31	PR	YES	Lorlatinib, 7.12; Alectinib + CBL0137. 0.31 Osimertinib + Gefitinib, 2.65;
P-38	P-38-O1T	M	52	1	IVB	ADC	Supraclavicular lymph node	EGFR L858R	2	Osimertinib + Radiotherapy	1.04	PD	YES	Osimertinib + PC, 5.91; EP, 10.76; PC 11.74
P-43	P-43-O1E	F	49	1	IVA	ADC	Pleural effusion	EGFR 19 del;T790M	2	AZD9291 generic drug	1.22	PD	YES	Docetaxel, 6.265E+150
P-49	P-49-O1E	M	70	3	IVB	ADC	Pleural effusion	Negative	3	Lorlatinib	13.01	PD	YES	NA
P-63	P-63-O3E	F	38	1	IVB	ADC	Pleural effusion	EML4-ALK fusion, ALK F1174C mutation	3	Alectinib	5.12	PD	YES	SAF-189s, 2.08; Lorlatinib, 16.54
P-75	P-75-O1E	M	58	1	IVB	ADC	Pleural effusion	ERBB2 20ins	1	Pyrotinib	0.05	PR	YES	PC, NA
P-75	P-75-O2E	M	58	1	IVB	ADC	Pleural effusion	ERBB2 20ins	1	Pyrotinib	0.49	PR	YES	PC, 18.88

P-86	P-86-O1E	F	74	1	IVA	ADC	Pleural effusion	MET 14 skipping	1	Bozitinib	810.6	SD	YES	Crizotinib, 6.28; Savolitinib, 2.88E+53 Osimertinib, NA; Gefitinib, NA
P-97	P-97-O1E	M	59	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M	2	PLB1004	2.48	PR	NO	Large panel DST [§]
P-97	P-97-O2E	M	59	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M	2	PLB1004	> 1000	PR	NO	Large panel DST [§]
P-97	P-97-O3E	M	59	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M	2	PLB1004	34.29	PR	NO	Large panel DST [§]
P-100	P-100-O1E	M	35	1	IVB	ADC	Pleural effusion	EGFR L858R;T790M	3	TQB3804	0.52	PD	NO	Large panel DST [§]
P-100	P-100-O2E	M	35	1	IVB	ADC	Pleural effusion	;cis-C797S mutation EGFR L858R;T790M	3	TQB3804	3.79	PD	YES	Large panel DST [§]
P-102	P-102-O1E	F	52	1	IVB	SCC	Pleural effusion	KIF5B-RET fusion	2	LOXO-292	5.7	PR	NO	Nab-paclitaxel + carboplatin, 15.30
P-105	P-105-O1T	M	59	1	IVB	SAR	Muscle mass	MET 14 skipping	1	Crizotinib	4.95	PD	YES	Savolitinib, 52.83
Dual targeted therapy group														
P-60	P-60-O1T	M	55	1	IVB	ADC	Lymph node	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	1.32	PR	YES	Osimertinib, 1.82
P-60	P-60-O2E	M	55	1	IVB	ADC	Pericardial effusion	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	0.71	PR	YES	Osimertinib, 1.15
P-60	P-60-O3E	M	55	1	IVB	ADC	Pericardial effusion	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	0.25	PR	YES	Osimertinib, 0.25; Savolitinib, 11.59
P-60	P-60-O4E	M	55	1	IVB	ADC	Pericardial effusion	EGFR L858R;MET amplification	2	Osimertinib + Savolitinib	0.24	PR	YES	Osimertinib, 1.30; Savolitinib, 17.61 Osimertinib, 3.68;
P-61	P-61-O1E	F	51	3	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib + Cabozantinib	0.15	PR	YES	BLU667, 0.76; Osimertinib + BLU667, 0.03; PC 19.41 Osimertinib, 3.37;
P-61	P-61-O2E	F	51	3	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib + Cabozantinib	0.22	PR	YES	BLU667, 2.09; Osimertinib + BLU667, 0.02; PC 27.10 Osimertinib, 5.16;
P-61	P-61-O3E	F	51	3	IVB	ADC	Ascitic effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib + Cabozantinib	0.16	PR	YES	BLU667, 0.22; Osimertinib + BLU667, 0.01; PC 21.65 Osimertinib, 11.31;
P-61	P-61-O4E	F	51	3	IVB	ADC	Pleural effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib + Cabozantinib	0.33	PR	YES	BLU667, 0.23; Osimertinib + BLU667, 0.03; PC 0.65 Osimertinib, 3.65;
P-61	P-61-O5E	F	51	3	IVB	ADC	Pleural effusion	EGFR 19 del;T790M,RET fusion	4	Osimertinib + Cabozantinib	0.44	PR	YES	BLU667, 0.51; Osimertinib + BLU667, 0.24; PC 17.12 Darafenib, NA
P-95	P-95-O2E	F	62	1	IVB	ADC	Pleural effusion	BRAF V600E	1	Darafenib + Trametinib	> 1000	SD	YES	Darafenib, NA
Chemotherapy group														
P-3	P-3-O1E	M	50	1	IVB	ADC	Pericardial effusion	EGFR 19 del	3	EP	6.635	PR	YES	Osimertinib, 0.013; Osimertinib + EP, 0.009; Osimertinib + PC, 0.012; Afatinib + EP 0.002 Ceritinib, 3.37; Lorlatinib, 18.31
P-25	P-25-O1E	F	32	1	IVB	ADC	Pleural effusion	CD74-ROS1 fusion, ROS1-intergenic fusion	3	PC	89.72	SD	YES	NA
P-50	P-50-O1E	M	69	1	IVA	SCLC	Pleural effusion	NA	1	EP	37.7	PD	YES	NA
P-51	P-51-O1E	M	63	1	IVB	SCC	Pleural effusion	Negative	1	Nab-paclitaxel + Carboplatin	10.91	PD	YES	GDC-0941, 2.17; Everolimus, 16.46 GDC-0941, 1.90;
P-51	P-51-O2E	M	63	1	IVB	SCC	Pleural effusion	Negative	1	Nab-paclitaxel + Carboplatin	14.29	PD	NO	Everolimus, 14.29 GDC-0941, 2.38;
P-51	P-51-O3E	M	63	1	IVB	SCC	Pleural effusion	Negative	1	Nab-paclitaxel + Carboplatin	2.05E+18	PD	NO	Everolimus, 32.54

P-65	P-65-O1E	M	66	1	IIIC	SCLC	Pleural effusion	NA	1	EP	20.9	PR	YES	NA
P-73	P-73-O1T	M	70	2	IVB	SCLC	Lymph node	NA	1	Nab-paclitaxel	5.03E+11	PD	YES	EP, 33.52
P-81	P-81-O1E	F	62	2	IVB	ADC	Pleural effusion	EGFR 19 del	3	Nab-paclitaxel	5.10E+15	PD	YES	Osimertinib, 1.46; Osimertinib + EP, 2.24
P-83	P-83-O1E	M	77	1	IVB	SCLC	Pleural effusion	NA	1	EC	95.89	SD	YES	NA Osimertinib, 19.34;
P-85	P-85-O1E	F	32	1	IVB	ADC	Ascitic effusion	EGFR 19 del	4	TDM1	6.88E+37	PD	YES	Osimertinib + Pyrotinib, 7.74; PC, 36.98
P-85	P-85-O2E	F	32	1	IVB	ADC	Ascitic effusion	EGFR 19 del	4	TDM1	8.28E+33	PD	YES	Osimertinib, 2.72; Osimertinib + Pyrotinib, 2.04; PC, 53.91

Abbreviations: LCO-DS1: Lung cancer organoid based drug sensitivity test; M: male; F: female; SCLC: small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; SAR: sarcomatoid carcinoma; NA: not available; IC50: half-maximal inhibitory concentration; Driver mutation: EGFR, ALK, HER2, MET, RET, ROS1, BRAF, KRAS; PC: Pemetrexed + Carboplatin; EP: Etoposide + Cisplatin; EC: Etoposide + Carboplatin.